WO1989001036A1 - Recombinant dna expression vectors - Google Patents

Recombinant dna expression vectors Download PDF

Info

Publication number
WO1989001036A1
WO1989001036A1 PCT/GB1988/000602 GB8800602W WO8901036A1 WO 1989001036 A1 WO1989001036 A1 WO 1989001036A1 GB 8800602 W GB8800602 W GB 8800602W WO 8901036 A1 WO8901036 A1 WO 8901036A1
Authority
WO
WIPO (PCT)
Prior art keywords
hcmv
gene
mie
dna
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1988/000602
Other languages
French (fr)
Inventor
Christopher Robert Bebbington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10621156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1989001036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech Ltd filed Critical Celltech Ltd
Priority to DE8888906008T priority Critical patent/DE3880468T2/en
Priority to AT88906008T priority patent/ATE88501T1/en
Publication of WO1989001036A1 publication Critical patent/WO1989001036A1/en
Anticipated expiration legal-status Critical
Priority to US08/300,063 priority patent/US5591639A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Definitions

  • This invention relates to expression vectors containing a DNA sequence from the human cytomegalovirus major immediate early gene, to host cells containing such vectors, to a method of producing a desired polypeptide by using vectors containing said sequence and to the use of said DNA sequence.
  • the main aim of workers in the field of recombinant DNA technology is to achieve as high a level of production as possible of a particular polypeptide. This is particularly true of commercial organisations who wish to exploit the use of recombinant DNA technology to produce polypeptides which naturally are not very abundant.
  • DNA technology involves the cloning of a gene encoding the desired polypeptide, placing the cloned gene in a suitable expression vector, transfecting a host cell line with the vector, and culturing the transfected cell line to produce the polypeptide. It is almost impossible to predict whether any particular vector or cell line or combination thereof will lead to a useful level of production.
  • the factors which significantly affect the amount of polypeptide produced by a transfected cell line are: 1. gene copy number, 2. efficiency with which the gene is transcribed' and the mRNA translated, 3. the stability of the mRNA and 4. the efficiency of secretion of the protein.
  • Virol 56 (1) 135-143, 1985 have used a PstI to PstI fragment of the hCMV-MIE gene encompassing the promoter, enhancer and part of the 5'-untranslated region, as a promoter for expression of heterologous genes. In order to obtain translation the natural 5'-untranslated region of the heterologous gene was used.
  • the stabilising sequence is placed in the 5'-untranslated region of the gene encoding the desired heterologous protein i.e. the teaching is again that the natural 5'-untranslated region of the gene is essential for translation.
  • the invention provides a vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus.
  • the vector in a preferred embodiment of the first aspect of the invention, includes a restriction site for insertion of a heterologous gene.
  • the present invention is based on the discovery that vectors containing a DNA sequence comprising the promoter, enhancer and complete 5'-untranslated region of the major immediate early gene of the human cytomegalovirus (hCMV-MIE) upstream of a heterologous gene result in high level expression of the heterologous gene product.
  • hCMV-MIE human cytomegalovirus
  • the invention provides a vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus upstream of a heterologous gene.
  • the hCMV-MIE derived DNA according to the second aspect of the invention may be separated from the coding sequence of the heterologous gene by intervening DNA such as for example by the 5'-untranslated region of the heterologous gene.
  • the hCMV-MIE derived DNA may be linked directly to the coding sequence of the heterologous gene.
  • the invention provides a vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene linked directly to the DNA coding sequence of the heterologous gene.
  • the hCMV-MIE derived sequence includes a sequence identical to the natural hCMV-MIE translation initiation signal. It may however be necessary or convenient to modify the natural translation initiation signal to facilitate linking the coding sequence of the desired polypeptide to the hCMV-MIE sequence, i.e. by introducing a convenient restriction enzyme recognition site.
  • the translation initiation site may advantageously be modified to provide an Ncol recognition site.
  • the heterologous gene may be a gene coding for any eukaryotic polypeptide such as for example a mammalian polypeptide such as an enzyme, e.g. chymosin or gastric lipase; an enzyme inhibitor, e.g. tissue inhibitor of metalloproteinase (TIMP); a hormone, e.g. growt hormone; a lymphokine, e.g. an interferon; a plasminogen activator, e.g. tissue plasminogen activator (tPA) or prourokinase; or a natural, modified or chimeric immunoglobulin or a fragment thereof including chimeric immunoglobulins having dual activity such as antibody-enzyme or antibody-toxin chimeras.
  • a mammalian polypeptide such as an enzyme, e.g. chymosin or gastric lipase; an enzyme inhibitor, e.g. tissue inhibitor of metalloproteinase (TIMP); a hormone, e
  • the host cell may be any eukaryotic cell such as for example plant, or insect cells but is preferably a mammalian cell such as for example CHO cells or cells of myeloid origin e.g. myeloma or hybridoma cells.
  • the invention provides a process for the production of a heterologous polypeptide by culturing a transfected cell according to the third aspect of the invention.
  • the invention provides the use of a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene for expression a heterologous gene.
  • the hCMV-MIE derived DNA sequence is linked directly to the DNA coding sequence of the heterologous gene.
  • plasmids pCMGS, pHT.1 and pEE6hCMV are also included within the scope of the invention.
  • Figure 1 shows a diagrammatic representation of plasmid pSVLGS.1
  • Figure 2 shows a diagrammatic representation of plasmid pHT.1
  • Figure 3 shows a diagrammatic representation of plasmid pCMGS
  • Figure 4 shows the complete sequence of the promoter-enhancer hCMV-MIE including both the first intron and a modified translation 'start' site
  • Figure 5 shows a diagrammatic representation of plasmid pEE6.hCMV Detailed Description of the Embodiments
  • the Pst-lm fragment of hCMV (Boshart et al Cell 41 521-530 (1985) Spaete & Mocarski J. Virol 56 (1) 135-143 (1985)) contains the promoter-enhancer and most of the 5'-untranslated leader of the MIE gene including the first intron. The remainder of the 5'untranslated sequence can be recreated by attaching a small additional sequence of approximately 20 base pairs.
  • Ncol restriction site 5'-CCATGG-3'
  • the hCMV-MIE gene does not have an Ncol site at the beginning of the protein coding sequence but a single base-pair alteration causes the sequence both to resemble more closely the "Kozak" concensus initiation signal and introduces an Ncol recognition site.
  • This synthetic DNA fragment was introduced between the hCMV Pst-lm promoter-enhancer leader fragment and a glutamine synthetase (GS) coding sequence by ligation of the Pst-lm fragment and the synthetic oligomer with Ncol digested pSV2.GS to generate a new plasmid, pCMGS (The production of pSV2.GS is described in published International Patent Application No. W0 8704462). pCMGS is shown in Figure 3.
  • pCMGS thus contains a hybrid transcription unit consisting of the following: the synthetic oligomer described above upstream of the hCMV-MIE promoter-enhancer (where it serves merely as a convenient Pstl - Ncol "adaptor"), the hCMV-MIE promoter and the complete 5' untranslated region of the MIE gene, including the first intron, fused directly to the GS coding sequence at the translation initiation site.
  • pCMGS was introduced into CHO-KI cells by calcium phosphate mediated transfection and the plasmid was tested for the ability to confer resistance to the GS-inhibitor methionine sulphoximine (MSX).
  • MSX GS-inhibitor methionine sulphoximine
  • pCMGS can confer resistance to 20 M MSX at a similar frequency to pSV2.GS, demonstrating that active GS enzyme is indeed expressed in this vector.
  • pEE6 is a bacterial vector from which sequences inhibitory to replication in mammalian cells have been removed. It contains the XmnI to Bcll portion of pCT54 (Emtage et al 1983 Proc. Natl. Acad. Sci. USA 80, 3671-3675) with a pSP64 (Melton et al 1984: Nucleic Acids. Res.
  • polylinker inserted in between the Hindlll and EcoRI sites.
  • the BamHI and Sall sites have been removed from the polylinker by digestion, filling in with Klenow enzyme and religation.
  • the Bcll to BamHI fragment is a 237 bp SV40 early polyadenylation signal
  • the BamHI to the Bgll fragment is derived from pBR328 (375 to 2422) with an additional deletion between the Sall and the Aval sites (651 to 1425) following the addition of a Sall linker to the Aval site.
  • the sequence from the Bgll to the XmnI site originates from the ⁇ -lactamase gene of pSP64.
  • the 2129 base-pair Ncol fragment containing the hCMV MIE promoter-enhancer and 5' untranslated sequence was isolated from pCMGS by partial Ncol digestion and inserted at the Ncol site overlapping the translation initiation signal of TIMP in pEE6.TIMP to generate the plasmid pHT.1 (shown in Figure 2).
  • a GS gene was introduced into pHT.1 to allow selection of permanent cell lines by introducing the 5.5K Pvul - BamHI fragment of pSVLGS.1 (figure 1) at the BamHI site of pHT.1 after addition of a synthetic BamHI linker to Pvul digested pSVLGS.1 to form pHT.1GS.
  • the hCMV-TIMP and GS transcription units transcribe in the same orientation.
  • pHT.1 GS was introduced into CHO-K1 cells by calcium-phosphate mediated transfection and clones resistant to 20uM MSX were isolated 2-3 weeks post-transfection.
  • TIMP secretion rates were determined by testing culture supernatants in a specific two site ELISA, based on a sheep anti TIMP polyclonal antibody as a capture antibody, a mouse TIMP monoclonal as the recognition antibody, binding of the monoclonal being revealed using a sheep anti mouse IgG peroxidase conjugate.
  • Purified natural TIMP was used as a standard for calibration of the assay and all curves were linear in the range of 2 - 20ng ml -1 . No non-specific reaction was detectable in CHO-cell conditioned culture media.
  • One cell line GS.19 was subsequently recloned, and a sub-clone GS 19-12 secretes TIMP at a very high level of 3 x 10 8 molecules/cell/day.
  • Total genomic DNA extracted from this cell line was hybridised with a TIMP probe by Southern blot analysis using standard techniques and shown to contain a single intact copy of the
  • TIMP transcription unit per cell (as well as two re-arranged plasmid bands). This cell line was selected for resistance to higher levels of MSX and in the first selection a pool of cells resistant to 500uM
  • MSX was isolated and recloned .
  • the clone GS-19.6(500)14 secretes 3 x 10 9 molecules TIMP/cell/day.
  • the vector copy-number in this cell line is approx. 20 - 30 copies/cell. Subsequent rounds of selection for further gene amplification did not led to increased
  • hCMV-TIMP transcription unit from pHT.1 can be very efficiently expressed in CHO-KI cells at approximately a single copy per cell and a single round of gene amplification leads to secretion rates which are maximal using current methods.
  • hCMV-MIE promoter-enhancer-leader can be used to direct the efficient expression of other protein sequences.
  • two different but related plasminogen activator coding sequences (designated PA-1 and PA-2) were introduced into CHO-KI cells in vectors in which the protein coding sequences were fused directly to the hCMV sequence.
  • Example 4 pEE6hCMV was made by ligating the Pst-lm fragment of hCMV, Hindlll- digested pEE6 and the complementary oligonucleotides of the sequence:
  • cDNA encoding an immunoglobulin light-chain was inserted at the EcoRI site of pEE6.hCMV such that the hCMV-MIE promoter-enhancer leader could direct expression of the cDNA and a selectable marker gene containing the SV40 origin of replication was inserted at the BamHI site of each plasmid.
  • This plasmid was transfected into COS-1 monkey kidney cells by a standard DEAE-dextran transfection procedure and transient expression was monitored 72 hours post transfection.
  • Light chain was secreted into the medium at at least 100ng/ml indicating that light chain can indeed be expressed from a transcription unit containing the entire hCMV-MIE 5'-untranslated sequence up to but not including the translation initiation ATG, followed by 15 bases of natural 5'-untranslated sequence of the mouse immunoglobulin light-chain gene.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Detection And Correction Of Errors (AREA)

Abstract

The invention provides expression vectors containing the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus. Further vectors including the hCMV-MIE DNA linked directly to the coding sequence of a heterologous gene are described. Host cells transfected with the vectors and a process for producing heterologous polypeptides using the vectors and the use of the hCMV-MIE DNA for expression of a heterologous gene are also included within the invention.

Description

RECOMBINANT DNA EXPRESSION VECTORS
Field of the Invention
This invention relates to expression vectors containing a DNA sequence from the human cytomegalovirus major immediate early gene, to host cells containing such vectors, to a method of producing a desired polypeptide by using vectors containing said sequence and to the use of said DNA sequence.
Background to the Invention
The main aim of workers in the field of recombinant DNA technology is to achieve as high a level of production as possible of a particular polypeptide. This is particularly true of commercial organisations who wish to exploit the use of recombinant DNA technology to produce polypeptides which naturally are not very abundant.
Generally the application of DNA technology involves the cloning of a gene encoding the desired polypeptide, placing the cloned gene in a suitable expression vector, transfecting a host cell line with the vector, and culturing the transfected cell line to produce the polypeptide. It is almost impossible to predict whether any particular vector or cell line or combination thereof will lead to a useful level of production.
In general, the factors which significantly affect the amount of polypeptide produced by a transfected cell line are: 1. gene copy number, 2. efficiency with which the gene is transcribed' and the mRNA translated, 3. the stability of the mRNA and 4. the efficiency of secretion of the protein.
The majority of work directed at increasing expression levels of recombinant polypeptides has focussed on improving transcription initiation mechanisms. As a result the factors affecting eff icient translation are much less well understood and defined, and generally it is not possible to predict whether any particular DNA sequences will be of use in obtaining efficient transaation. Attempts at investigating translation have consisted largely of varying the DNA sequence around the consensus translation start signal to determine what effect this has on translation initiation (Kozak M. Cell 41 283-292 (1986)).
Studies involving expression of desired heterologous genes normally use both the coding sequence and at least part of the 5'-untranslated sequence of the heterologous gene such that translation initiation is from the natural sequence of the gene. This approach has been found to be unreliable probably as a result of the "hybrid nature' of the 5'-untranslated region and the fact that the presence of particular 5-untranslated sequences can lead to poor initiation of translation (Kozak M. Procl. Natl. Acad. Sci. 83 2850-2854 (1986) and Pelletier and Sonenberg Cell 40 515-526 (1985)). This variation in translation has a detrimental effect on the amount of the product produced.
Previous studies (Boshart et al Cell 41 521-530 (1985) and Pasleau et al, Gene 38 227-232 (1985); Stenberg et al, J. Virol 49 (1) 190-199 (1984); Thomsen et al Proc. Natl. Acad. Sci. USA 81659-663 (1984) and Foecking and Hofstetter Gene 45 101-105 (1986)) have used sequences from the upstream region of the hCMV-MIE gene in expression vectors. These have, however, solely been concerned with the use of the sequences as promoters and/or enhancers. Spaete and Mocarski (J. Virol 56 (1) 135-143, 1985) have used a PstI to PstI fragment of the hCMV-MIE gene encompassing the promoter, enhancer and part of the 5'-untranslated region, as a promoter for expression of heterologous genes. In order to obtain translation the natural 5'-untranslated region of the heterologous gene was used.
In published European Patent Application No. 260148, a method for the continuous production of a heterologous protein is described. The expression vectors constructed contain part of the
5'-untranslated region of the hCMV-MIE gene as a stabilising sequence. The stabilising sequence is placed in the 5'-untranslated region of the gene encoding the desired heterologous protein i.e. the teaching is again that the natural 5'-untranslated region of the gene is essential for translation.
Summary of the Invention
In a first aspect the invention provides a vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus.
in a preferred embodiment of the first aspect of the invention, the vector includes a restriction site for insertion of a heterologous gene.
The present invention is based on the discovery that vectors containing a DNA sequence comprising the promoter, enhancer and complete 5'-untranslated region of the major immediate early gene of the human cytomegalovirus (hCMV-MIE) upstream of a heterologous gene result in high level expression of the heterologous gene product. In particular, we have unexpectedly found that when the hCMV-MIE derived DNA is linked directly to the coding sequence of the heterologous gene high levels of mRNA translation are achieved. This efficient translation of mRNA is achieved consistently and appears to be independent of the particular heterologous gene being expressed.
In a second aspect the invention provides a vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus upstream of a heterologous gene.
The hCMV-MIE derived DNA according to the second aspect of the invention may be separated from the coding sequence of the heterologous gene by intervening DNA such as for example by the 5'-untranslated region of the heterologous gene. Advantageously the hCMV-MIE derived DNA may be linked directly to the coding sequence of the heterologous gene.
In a preferred embodiment of the second aspect of the invention, the invention provides a vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene linked directly to the DNA coding sequence of the heterologous gene.
Preferably the hCMV-MIE derived sequence includes a sequence identical to the natural hCMV-MIE translation initiation signal. It may however be necessary or convenient to modify the natural translation initiation signal to facilitate linking the coding sequence of the desired polypeptide to the hCMV-MIE sequence, i.e. by introducing a convenient restriction enzyme recognition site. For example the translation initiation site may advantageously be modified to provide an Ncol recognition site.
The heterologous gene may be a gene coding for any eukaryotic polypeptide such as for example a mammalian polypeptide such as an enzyme, e.g. chymosin or gastric lipase; an enzyme inhibitor, e.g. tissue inhibitor of metalloproteinase (TIMP); a hormone, e.g. growt hormone; a lymphokine, e.g. an interferon; a plasminogen activator, e.g. tissue plasminogen activator (tPA) or prourokinase; or a natural, modified or chimeric immunoglobulin or a fragment thereof including chimeric immunoglobulins having dual activity such as antibody-enzyme or antibody-toxin chimeras.
According to a third aspect of the invention there is provided host cells transfected with vectors according to the first or second aspect of the invention. The host cell may be any eukaryotic cell such as for example plant, or insect cells but is preferably a mammalian cell such as for example CHO cells or cells of myeloid origin e.g. myeloma or hybridoma cells.
In a fourth aspect the invention provides a process for the production of a heterologous polypeptide by culturing a transfected cell according to the third aspect of the invention.
In a fifth aspect the invention provides the use of a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene for expression a heterologous gene.
In a preferred embodiment of the fifth aspect of the invention the hCMV-MIE derived DNA sequence is linked directly to the DNA coding sequence of the heterologous gene.
Also included within the scope of the invention are plasmids pCMGS, pHT.1 and pEE6hCMV.
Brief Description of the Drawings
The present invention is now described, by way of example only, with reference to the accompanying drawings in which
Figure 1: shows a diagrammatic representation of plasmid pSVLGS.1 Figure 2: shows a diagrammatic representation of plasmid pHT.1 Figure 3: shows a diagrammatic representation of plasmid pCMGS Figure 4: shows the complete sequence of the promoter-enhancer hCMV-MIE including both the first intron and a modified translation 'start' site
Figure 5: shows a diagrammatic representation of plasmid pEE6.hCMV Detailed Description of the Embodiments
Example 1
The Pst-lm fragment of hCMV (Boshart et al Cell 41 521-530 (1985) Spaete & Mocarski J. Virol 56 (1) 135-143 (1985)) contains the promoter-enhancer and most of the 5'-untranslated leader of the MIE gene including the first intron. The remainder of the 5'untranslated sequence can be recreated by attaching a small additional sequence of approximately 20 base pairs.
Many eukaryotic genes contain an Ncol restriction site (5'-CCATGG-3') overlapping the translation start site, since this sequence frequently forms part of a preferred translation initiation signal 5'ACCATGPu-3'. The hCMV-MIE gene does not have an Ncol site at the beginning of the protein coding sequence but a single base-pair alteration causes the sequence both to resemble more closely the "Kozak" concensus initiation signal and introduces an Ncol recognition site. Therefore a pair of complementary oligonucleotides were synthesised of the sequence:
Figure imgf000008_0001
which when fused to the Pst-lm fragment of hCMV will recreate the complete 5'-untranslated sequence of the MIE gene with the single alteration of a G to a C at position -1 relative to the translation initiation codon.
This synthetic DNA fragment was introduced between the hCMV Pst-lm promoter-enhancer leader fragment and a glutamine synthetase (GS) coding sequence by ligation of the Pst-lm fragment and the synthetic oligomer with Ncol digested pSV2.GS to generate a new plasmid, pCMGS (The production of pSV2.GS is described in published International Patent Application No. W0 8704462). pCMGS is shown in Figure 3. pCMGS thus contains a hybrid transcription unit consisting of the following: the synthetic oligomer described above upstream of the hCMV-MIE promoter-enhancer (where it serves merely as a convenient Pstl - Ncol "adaptor"), the hCMV-MIE promoter and the complete 5' untranslated region of the MIE gene, including the first intron, fused directly to the GS coding sequence at the translation initiation site.
pCMGS was introduced into CHO-KI cells by calcium phosphate mediated transfection and the plasmid was tested for the ability to confer resistance to the GS-inhibitor methionine sulphoximine (MSX). The results of a comparison with pSV2.GS are shown in Table 1.
It is clear that pCMGS can confer resistance to 20 M MSX at a similar frequency to pSV2.GS, demonstrating that active GS enzyme is indeed expressed in this vector.
Figure imgf000009_0001
Example 2
The TIMP cDNA and SV40 polyadenylation signal as used in pTIMP 1 Docherty et al (1985) Nature 318, 66-69, was inserted into pEE6 between the unique Hindlll and BamHI sites to create pEE6TIMP. pEE6 is a bacterial vector from which sequences inhibitory to replication in mammalian cells have been removed. It contains the XmnI to Bcll portion of pCT54 (Emtage et al 1983 Proc. Natl. Acad. Sci. USA 80, 3671-3675) with a pSP64 (Melton et al 1984: Nucleic Acids. Res. 12, 7035) polylinker inserted in between the Hindlll and EcoRI sites. The BamHI and Sall sites have been removed from the polylinker by digestion, filling in with Klenow enzyme and religation. The Bcll to BamHI fragment is a 237 bp SV40 early polyadenylation signal
(SV40 2770 to 2533). The BamHI to the Bgll fragment is derived from pBR328 (375 to 2422) with an additional deletion between the Sall and the Aval sites (651 to 1425) following the addition of a Sall linker to the Aval site. The sequence from the Bgll to the XmnI site originates from the β-lactamase gene of pSP64.
The 2129 base-pair Ncol fragment containing the hCMV MIE promoter-enhancer and 5' untranslated sequence was isolated from pCMGS by partial Ncol digestion and inserted at the Ncol site overlapping the translation initiation signal of TIMP in pEE6.TIMP to generate the plasmid pHT.1 (shown in Figure 2).
A GS gene was introduced into pHT.1 to allow selection of permanent cell lines by introducing the 5.5K Pvul - BamHI fragment of pSVLGS.1 (figure 1) at the BamHI site of pHT.1 after addition of a synthetic BamHI linker to Pvul digested pSVLGS.1 to form pHT.1GS. In this plasmid the hCMV-TIMP and GS transcription units transcribe in the same orientation.
pHT.1 GS was introduced into CHO-K1 cells by calcium-phosphate mediated transfection and clones resistant to 20uM MSX were isolated 2-3 weeks post-transfection. TIMP secretion rates were determined by testing culture supernatants in a specific two site ELISA, based on a sheep anti TIMP polyclonal antibody as a capture antibody, a mouse TIMP monoclonal as the recognition antibody, binding of the monoclonal being revealed using a sheep anti mouse IgG peroxidase conjugate. Purified natural TIMP was used as a standard for calibration of the assay and all curves were linear in the range of 2 - 20ng ml-1. No non-specific reaction was detectable in CHO-cell conditioned culture media. One cell line GS.19 was subsequently recloned, and a sub-clone GS 19-12 secretes TIMP at a very high level of 3 x 108 molecules/cell/day. Total genomic DNA extracted from this cell line was hybridised with a TIMP probe by Southern blot analysis using standard techniques and shown to contain a single intact copy of the
TIMP transcription unit per cell (as well as two re-arranged plasmid bands). This cell line was selected for resistance to higher levels of MSX and in the first selection a pool of cells resistant to 500uM
MSX was isolated and recloned . The clone GS-19.6(500)14 secretes 3 x 109 molecules TIMP/cell/day. The vector copy-number in this cell line is approx. 20 - 30 copies/cell. Subsequent rounds of selection for further gene amplification did not led to increased
TIMP secretion.
Thus it appears that the hCMV-TIMP transcription unit from pHT.1 can be very efficiently expressed in CHO-KI cells at approximately a single copy per cell and a single round of gene amplification leads to secretion rates which are maximal using current methods.
Example 3
In order to test whether the hCMV-MIE promoter-enhancer-leader can be used to direct the efficient expression of other protein sequences, two different but related plasminogen activator coding sequences (designated PA-1 and PA-2) were introduced into CHO-KI cells in vectors in which the protein coding sequences were fused directly to the hCMV sequence.
In both these cases, there is no Ncol site at the beginning of the translated sequence and so synthetic oligonucleotides were used to recreate the authentic coding sequence from suitable restriction sites within the translated region. The sequence of the modified hCMV translation-initiation signal as used in pHT.1 was also built into the synthetic oligonucleotide which then ended in a Pst-1 restriction site. The Pst-lm fragment of hCMV was then inserted at this site to create the complete promoter-enhancer-leader sequenee. The hCMV-plasminogen activator transcription units were introduced into CHO-KI cells after inserting a GS gene at the unique BamHI site as above and MSX resistant cell lines secreting plasminogen activator were isolated.
The secretion rates of the best initial transfectant cell lines in each case are given in Table 2. From this it is clear that the hCMV promoter-enhancer leader can also be used to direct the efficient expression of these two plasminogen activator proteins .
Table 2 Secretion rates of the different plasminogen activator proteins from transfectant CHO cell lines.
Figure imgf000012_0002
Example 4 pEE6hCMV was made by ligating the Pst-lm fragment of hCMV, Hindlll- digested pEE6 and the complementary oligonucleotides of the sequence:
Figure imgf000012_0001
cDNA encoding an immunoglobulin light-chain was inserted at the EcoRI site of pEE6.hCMV such that the hCMV-MIE promoter-enhancer leader could direct expression of the cDNA and a selectable marker gene containing the SV40 origin of replication was inserted at the BamHI site of each plasmid. This plasmid was transfected into COS-1 monkey kidney cells by a standard DEAE-dextran transfection procedure and transient expression was monitored 72 hours post transfection. Light chain was secreted into the medium at at least 100ng/ml indicating that light chain can indeed be expressed from a transcription unit containing the entire hCMV-MIE 5'-untranslated sequence up to but not including the translation initiation ATG, followed by 15 bases of natural 5'-untranslated sequence of the mouse immunoglobulin light-chain gene.

Claims

1. A vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene.
2 A vector according to claim 1 wherein the vector includes a restriction site for insertion of a heterologous gene.
3. A vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene upstream of a heterologous gene.
4. A vector according to Claim 3 wherein the hCMV-MIE DNA is linked directly to the DNA coding sequence of a heterologous gene.
5. A vector according to Claim 4 wherein the hCMV-MIE DNA includes a translation initiation signal.
6. A host cell transfected with a vector according to any of the preceeding claims.
7. A process for the production of a heterologous polypeptide by culturing a host cell according to Claim 6.
8. The use of a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene for expression of a heterologous gene.
9. The use of a DNA sequence according to Claim 8 wherein the hCMV-MIE derived DNA is linked directly to the coding sequence of the heterologous gene.
10. Plasmids pCMGS, pEE6.hCMV and pHT.1
PCT/GB1988/000602 1987-07-23 1988-07-22 Recombinant dna expression vectors Ceased WO1989001036A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE8888906008T DE3880468T2 (en) 1987-07-23 1988-07-22 RECOMBINANT DNS EXPRESSION VECTORS.
AT88906008T ATE88501T1 (en) 1987-07-23 1988-07-22 RECOMBINANT DNA EXPRESSION VECTORS.
US08/300,063 US5591639A (en) 1987-07-23 1994-09-02 Recombinant DNA expression vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8717430 1987-07-23
GB878717430A GB8717430D0 (en) 1987-07-23 1987-07-23 Recombinant dna product

Publications (1)

Publication Number Publication Date
WO1989001036A1 true WO1989001036A1 (en) 1989-02-09

Family

ID=10621156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1988/000602 Ceased WO1989001036A1 (en) 1987-07-23 1988-07-22 Recombinant dna expression vectors

Country Status (7)

Country Link
US (2) US5591639A (en)
EP (1) EP0323997B1 (en)
JP (1) JP2505268B2 (en)
AT (1) ATE88501T1 (en)
DE (1) DE3880468T2 (en)
GB (1) GB8717430D0 (en)
WO (1) WO1989001036A1 (en)

Cited By (515)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009118A3 (en) * 1989-12-07 1991-10-31 British Bio Technology Activatable fibrinolytic and anti-thrombotic proteins
WO1993023542A1 (en) 1992-05-08 1993-11-25 The Biotechnology And Biological Sciences Research Recombinant dna molecules encoding aminopeptidase enzymes and their use in the preparation of vaccines against helminth infections
EP0396083B1 (en) * 1989-05-01 1994-11-30 Schering Corporation Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use
WO1995011982A1 (en) * 1993-10-25 1995-05-04 Menarini Ricerche Sud S.P.A. Expression system for eukaryotic cell lines
WO1996017063A1 (en) * 1994-11-28 1996-06-06 Vical Incorporated Plasmids suitable for il-2 expression
WO1997003997A1 (en) * 1995-07-19 1997-02-06 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
WO1997045535A1 (en) * 1996-05-24 1997-12-04 Novartis Ag Recombinant rna 3'-terminal phosphate cyclases and production methods thereof
WO1998033807A1 (en) * 1997-02-04 1998-08-06 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
WO1999003981A1 (en) * 1997-07-17 1999-01-28 Ppl Therapeutics (Scotland) Limited Nucleic acid expression constructs incorporating a heterologous intron whose natural position is within the 5'untranslated region of its gene
WO2000023592A3 (en) * 1998-10-19 2000-07-27 Powderject Vaccines Inc Minimal promoters and uses thereof
US6150339A (en) * 1993-04-23 2000-11-21 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
US6288042B1 (en) 1993-04-23 2001-09-11 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
US6323185B1 (en) * 1993-04-23 2001-11-27 The United States Of America As Represented By The Department Of Health And Human Services Anti-viral guanosine-rich oligonucleotides and method of treating HIV
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2002043660A2 (en) 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP1147205A4 (en) * 1998-12-31 2003-01-08 Viromed Ltd High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site
US6602503B1 (en) 1993-01-12 2003-08-05 Biogen, Inc. Recombinant anti-VLA-4 antibody molecules
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
WO2004073737A1 (en) 2003-02-19 2004-09-02 Merial Limited Vaccination or immunization using a prime-boost regimen against brsv, bhv-1, bvdv, bpi-3
WO2005062972A2 (en) 2003-12-23 2005-07-14 Tanox, Inc. Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005085448A2 (en) 2003-05-01 2005-09-15 Merial Limited Canine ghrh gene, polypeptides and methdos of use
WO2005090564A1 (en) 2004-03-19 2005-09-29 Genomidea Inc. Gene promoting vascular endothelial cell growth
WO2005117967A2 (en) 2004-04-12 2005-12-15 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
US7074590B2 (en) 2000-06-23 2006-07-11 Maxygen, Inc. Chimeric promoters
EP1594955A4 (en) * 2003-02-14 2006-07-19 Biogen Idec Inc An expression cassette and vector for transient or stable expression of exogenous molecules
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
WO2006102095A2 (en) 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
WO2007038637A2 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
WO2007067992A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7259002B2 (en) 2003-01-21 2007-08-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
US7279568B2 (en) 1998-12-31 2007-10-09 Viromed Limited Highly efficient eukaryotic expression vector comprising an exogenous transcription regulatory element
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
WO2007141280A2 (en) 2006-06-06 2007-12-13 Oxford Genome Sciences (Uk) Ltd Proteins
WO2008018641A1 (en) 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
WO2008030611A2 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
WO2008070569A2 (en) 2006-12-01 2008-06-12 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
WO2008074004A2 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
WO2008076560A2 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
US7393534B2 (en) 2003-07-15 2008-07-01 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
EP1961428A1 (en) 2002-04-02 2008-08-27 Ucb S.A. SC6 antibody for treatment of cancer
WO2008105797A2 (en) 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucleotides encoding novel pcsk9 variants
WO2008108918A1 (en) 2007-02-21 2008-09-12 University Of Massachusetts Human antibodies against hepatitis c virus (hcv) uses thereof
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
WO2008136790A1 (en) 2007-05-02 2008-11-13 Merial Limited Dna plasmids having improved expression and stability
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2008145338A2 (en) 2007-05-29 2008-12-04 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US7473534B2 (en) 2002-03-01 2009-01-06 Siemens Healthcare Diagnostics Inc. Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples
WO2009032845A2 (en) 2007-09-04 2009-03-12 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2009054863A2 (en) 2006-12-13 2009-04-30 Medarex, Inc. Human antibodies that bind cd19 and uses thereof
WO2009058322A1 (en) 2007-10-31 2009-05-07 Human Genome Sciences, Inc. Albumin fusion proteins
WO2009061818A1 (en) 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
EP2075346A2 (en) 2002-01-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Gene products differentially expressed in cancerous breast cells and their methods of use
EP2080766A1 (en) 2001-06-06 2009-07-22 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides useful for immunomodulation
WO2009092011A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
EP2085467A2 (en) 2002-10-29 2009-08-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia Longipalpis polypeptides and methods of use
WO2009100309A2 (en) 2008-02-08 2009-08-13 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
WO2009102488A2 (en) 2008-02-15 2009-08-20 Tufts University A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
EP2100619A1 (en) 2003-02-20 2009-09-16 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
EP2158917A1 (en) 2002-09-19 2010-03-03 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services P.ariasi polypeptides, P.perniciosus polypeptides and methods of use
EP2161336A1 (en) 2005-05-09 2010-03-10 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2186823A1 (en) 2005-11-14 2010-05-19 Merial Limited Gene therapy for renal failure
WO2010055366A2 (en) 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
US7732159B2 (en) 2002-03-01 2010-06-08 Siemens Healthcare Diagnostics Inc. Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2198881A1 (en) 2005-04-25 2010-06-23 Merial Limited Nipah virus vaccines
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
WO2010078526A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
WO2010084408A2 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EP2221316A1 (en) 2005-05-05 2010-08-25 Duke University Anti-CD19 antibody therapy for autoimmune disease
US7785829B2 (en) 2003-03-19 2010-08-31 Biogen Idec Ma, Inc. Nogo receptor binding protein
WO2010102175A1 (en) 2009-03-05 2010-09-10 Medarex, Inc. Fully human antibodies specific to cadm1
EP2228071A1 (en) 2006-11-14 2010-09-15 Merial Limited Intra-vascular kidney gene therapy with plasmid encoding BMP-7
EP2228389A2 (en) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
WO2010112458A1 (en) 2009-03-31 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
EP2238986A2 (en) 2005-07-08 2010-10-13 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
WO2010125003A1 (en) 2009-04-27 2010-11-04 Novartis Ag Compositions and methods for increasing muscle growth
WO2010128398A1 (en) 2009-05-04 2010-11-11 Pangenetics 110 B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
EP2260858A2 (en) 2003-11-06 2010-12-15 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
EP2270045A1 (en) 2004-02-06 2011-01-05 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
EP2272566A2 (en) 2003-08-18 2011-01-12 MedImmune, LLC Humanisation of antibodies
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
EP2292663A2 (en) 2006-08-28 2011-03-09 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
EP2295469A2 (en) 2005-11-24 2011-03-16 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
WO2011044180A1 (en) 2009-10-06 2011-04-14 Bristol-Myers Squibb Company Methods of production of glycoproteins in mammalian cell cultures using glucocorticoids
WO2011047083A1 (en) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Antibodies against epha10
EP2316856A1 (en) 2002-10-17 2011-05-04 Genmab A/S Human monoclonal antibodies against CD20
EP2316487A1 (en) 2003-04-11 2011-05-04 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011056073A2 (en) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
WO2011057788A1 (en) 2009-11-11 2011-05-19 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2329714A1 (en) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Influence of TAJ in the neuronal functions
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
EP2341144A1 (en) 1999-01-11 2011-07-06 Schering Corporation Interleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
WO2011090708A2 (en) 2009-12-28 2011-07-28 Merial Limited Recombinant ndv antigen and uses thereof
EP2353611A2 (en) 2002-07-31 2011-08-10 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP2364994A1 (en) 1994-01-05 2011-09-14 Schering Corporation Purfied primate CTLA-8 antigens and related reagents
WO2011112955A1 (en) 2010-03-12 2011-09-15 Merial Limited Bluetongue virus recombinant vaccines and uses thereof
WO2011116090A1 (en) 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
WO2011116885A1 (en) 2010-03-23 2011-09-29 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
EP2377886A1 (en) 2005-12-12 2011-10-19 F. Hoffmann-La Roche AG Antibody glycosylation in the variable region
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
EP2383295A1 (en) 2003-12-10 2011-11-02 Medarex, Inc. IP-10 antibodies and their uses
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP2404615A1 (en) 2003-04-23 2012-01-11 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
EP2407548A1 (en) 2006-10-16 2012-01-18 MedImmune, LLC Molecules with reduced half-lives, compositions and uses thereof
US8114606B2 (en) 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
EP2418220A2 (en) 2003-12-10 2012-02-15 Medarex, Inc. Interferon alpha antibodies and their uses
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2012031099A2 (en) 2010-09-02 2012-03-08 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
WO2012032433A1 (en) 2010-09-09 2012-03-15 Pfizer Inc. 4-1bb binding molecules
EP2431054A2 (en) 2000-06-15 2012-03-21 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
WO2012045752A1 (en) 2010-10-04 2012-04-12 Boehringer Ingelheim International Gmbh Cd33 binding agents
WO2012045703A1 (en) 2010-10-05 2012-04-12 Novartis Ag Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
EP2441775A1 (en) 2007-02-26 2012-04-18 Oxford Biotherapeutics Ltd. Protein
WO2012049570A1 (en) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Human anti-tau antibodies
EP2447719A1 (en) 2007-02-26 2012-05-02 Oxford Biotherapeutics Ltd. Proteins
WO2012058768A1 (en) 2010-11-05 2012-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2012065950A1 (en) 2010-11-15 2012-05-24 Novartis Ag Silent fc variants of anti-cd40 antibodies
WO2012080518A1 (en) 2010-12-17 2012-06-21 Neurimmune Holding Ag Human anti-sod1 antibodies
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
US8221983B2 (en) 2000-06-02 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2487189A1 (en) 2007-03-14 2012-08-15 GANYMED Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2486941A1 (en) 2006-10-02 2012-08-15 Medarex, Inc. Human antibodies that bind CXCR4 and uses thereof
EP2500030A2 (en) 2005-11-04 2012-09-19 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
EP2510934A1 (en) 2005-11-04 2012-10-17 Biogen Idec MA Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
WO2012140627A1 (en) 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
WO2012156018A1 (en) 2011-05-13 2012-11-22 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
EP2526968A2 (en) 2006-01-27 2012-11-28 Biogen Idec MA Inc. Nogo receptor antagonists
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2530090A2 (en) 2006-10-19 2012-12-05 CSL Limited Anti-IL-13R alpha 1 antibodies and their uses thereof
WO2012166493A1 (en) 2011-06-01 2012-12-06 Merial Limited Needle-free administration of prrsv vaccines
EP2535355A2 (en) 2005-03-23 2012-12-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2012177972A1 (en) 2011-06-23 2012-12-27 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2013003625A2 (en) 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Antibodies
WO2013001369A2 (en) 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
WO2013003606A1 (en) 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
EP2543384A2 (en) 2005-12-02 2013-01-09 Biogen Idec MA Inc. Treatment of conditions involving demyelination
WO2013006437A1 (en) 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
WO2013008171A1 (en) 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
WO2013012446A1 (en) 2011-07-20 2013-01-24 Merial Limited Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
US8388965B2 (en) 2007-10-15 2013-03-05 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2567709A2 (en) 2007-11-02 2013-03-13 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
EP2567973A2 (en) 2005-11-28 2013-03-13 Zymogenetics, Inc. IL-21 antagonists
WO2013034660A1 (en) 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
EP2570432A1 (en) 2002-06-14 2013-03-20 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP2570137A2 (en) 2007-11-07 2013-03-20 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2586796A1 (en) 2007-10-12 2013-05-01 Novartis AG Compositions and methods for use for antibodies against sclerostin
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
WO2013078118A1 (en) 2011-11-21 2013-05-30 Bristol-Myers Squibb Company Methods for determining the susceptibility of a virus to an attachment inhibitor
EP2599791A1 (en) 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
EP2604280A2 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2610267A1 (en) 2006-12-18 2013-07-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
EP2609932A2 (en) 2006-12-01 2013-07-03 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2013119960A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Novel modulators and methods of use
EP2641612A1 (en) 2008-02-05 2013-09-25 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
WO2013142371A1 (en) 2012-03-20 2013-09-26 Merial Limited Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
EP2662386A1 (en) 2012-05-07 2013-11-13 BioNTech AG Antibodies that bind to PLAC1 and block interaction between PLAC1 and FGF7
EP2662390A1 (en) 2004-06-21 2013-11-13 Medarex, L.L.C. Interferon alpha receptor 1 antibodies and their uses
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
WO2013167259A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies against claudin 18.2 useful in cancer diagnosis
WO2013174509A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174510A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013183032A2 (en) 2012-06-08 2013-12-12 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
WO2013188673A2 (en) 2012-06-13 2013-12-19 Merial Limited Reassortant btv and ahsv vaccines
WO2014008218A1 (en) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2014020331A1 (en) 2012-08-01 2014-02-06 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
US8647622B2 (en) 2007-08-29 2014-02-11 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US8653020B2 (en) 2008-01-25 2014-02-18 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
EP2703007A1 (en) 2007-03-30 2014-03-05 MedImmune, LLC Antibodies with decreased deamidation profiles
EP2703011A2 (en) 2007-05-07 2014-03-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2014058875A2 (en) 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
EP2722051A1 (en) 2005-07-07 2014-04-23 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
WO2014062535A1 (en) 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
EP2740744A2 (en) 2007-01-09 2014-06-11 Biogen Idec MA Inc. SP35 antibodies and uses thereof
WO2014102399A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
WO2014106602A1 (en) 2013-01-02 2014-07-10 Glenmark Pharmaceuticals S.A. Antibodies that bind to tl1a and their uses
EP2759307A2 (en) 2006-03-29 2014-07-30 Merial Limited Vaccine against Streptococci
WO2014122613A1 (en) 2013-02-08 2014-08-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EP2769993A1 (en) 2007-12-14 2014-08-27 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
EP2769737A1 (en) 2009-07-20 2014-08-27 Bristol-Myers Squibb Company Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014130879A2 (en) 2013-02-22 2014-08-28 Stem Centrx, Inc. Novel antibody conjugates and uses thereof
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014186364A2 (en) 2013-05-13 2014-11-20 Tufts University Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
WO2014197849A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
US8937169B2 (en) 1996-01-11 2015-01-20 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP2829551A1 (en) 2006-10-19 2015-01-28 CSL Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
WO2015022658A2 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
US8975375B2 (en) 2005-09-12 2015-03-10 Ganymed Pharmaceuticals Ag Identification of tumor-associated antigens for diagnosis and therapy
WO2015053871A2 (en) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
EP2868328A1 (en) 2013-10-31 2015-05-06 Universitätsklinikum Regensburg IL-3 blockade in systemic lupus erythematosus and multiple sclerosis
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
EP2899203A2 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
EP2905030A1 (en) 2008-08-11 2015-08-12 E. R. Squibb & Sons, L.L.C. Human antibodies that bind lymphocyte activation gene-3 (LAG-3) and uses thereof
EP2910645A1 (en) 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis upon antibody treatment
WO2015162590A1 (en) 2014-04-24 2015-10-29 Novartis Ag Methods of improving or accelerating physical recovery after surgery for hip fracture
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
WO2015187811A2 (en) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
EP2982379A1 (en) 2005-07-01 2016-02-10 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2016011448A3 (en) * 2014-07-18 2016-03-10 Celltheon Corporation Methods and compositions for expression of polypeptides in a cell
EP3002298A1 (en) 2007-11-21 2016-04-06 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
WO2016050822A2 (en) 2014-09-30 2016-04-07 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
US9316645B2 (en) 2011-10-07 2016-04-19 Brown University Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging
EP3009454A2 (en) 2009-04-20 2016-04-20 Oxford Bio Therapeutics Limited Antibodies specific to cadherin-17
WO2016073410A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
WO2016097865A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
WO2016106221A1 (en) 2014-12-22 2016-06-30 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
WO2016134335A2 (en) 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
EP3072525A1 (en) 2007-05-14 2016-09-28 MedImmune, LLC Methods of reducing basophil levels
WO2016164305A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
WO2016166124A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016166122A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016179517A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
EP3095797A1 (en) 2012-02-24 2016-11-23 Stemcentrx, Inc. Anti dll3 antibodies and methods of use thereof
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2016210094A1 (en) 2015-06-23 2016-12-29 Merial, Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
WO2017009712A1 (en) 2015-07-13 2017-01-19 Compugen Ltd. Hide1 compositions and methods
EP3124613A1 (en) 2009-05-22 2017-02-01 Merial, Inc. Antibiotic-free plasmid
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2017031353A1 (en) 2015-08-19 2017-02-23 Rutgers, The State University Of New Jersey Novel methods of generating antibodies
WO2017031120A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2017048902A1 (en) 2015-09-15 2017-03-23 Board Of Regents, The University Of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
WO2017058521A1 (en) 2015-09-29 2017-04-06 Merial, Inc. Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
US9617336B2 (en) 2012-02-01 2017-04-11 Compugen Ltd C10RF32 antibodies, and uses thereof for treatment of cancer
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
EP3168307A1 (en) 2008-11-28 2017-05-17 Merial Limited Recombinant avian influenza vaccine and uses thereof
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017084078A1 (en) 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2017132666A1 (en) 2016-01-29 2017-08-03 Merial, Inc. Recombinant adenovirus vectored fmdv vaccines and uses thereof
WO2017141208A1 (en) 2016-02-17 2017-08-24 Novartis Ag Tgfbeta 2 antibodies
WO2017151176A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
WO2017152085A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017156298A1 (en) 2016-03-10 2017-09-14 Medimmune, Llc Ilt7 binding molecules and methods of using the same
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
WO2017196663A1 (en) 2016-05-09 2017-11-16 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
WO2017205721A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2017207694A1 (en) 2016-06-02 2017-12-07 Kohlmann Angelica Antibodies that bind to human anti-müllerian hormone (amh) and their uses
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
EP3254695A1 (en) 2012-05-23 2017-12-13 GANYMED Pharmaceuticals AG Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3260137A1 (en) 2008-01-28 2017-12-27 Merial, Inc. Canine influenza vaccines
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3269740A1 (en) 2016-07-13 2018-01-17 Mabimmune Diagnostics AG Novel anti-fibroblast activation protein (fap) binding agents and uses thereof
WO2018013818A2 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018013714A1 (en) 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2018054973A1 (en) 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
WO2018071822A2 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
EP3320920A1 (en) 2009-05-08 2018-05-16 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
DE112016004398T5 (en) 2015-09-28 2018-06-14 Limited Liability Company "Oncomax" (Llc "Oncomax") THE ANTIBODIES THAT SPECIFICALLY BIND THE TYPE-1 RECEPTOR OF THE FIBROBLAST GROWTH FACTOR, THE USE OF ANTIBODIES FOR THE TREATMENT OF ONCOLOGICAL DISEASES, A PROCESS FOR THE PREPARATION OF THE ANTIBODIES
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
EP3338793A1 (en) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
US10053510B2 (en) 2013-05-24 2018-08-21 Promis Neurosciences Inc. FasR antibodies and methods of use
WO2018151821A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2018175460A1 (en) 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP3385280A1 (en) 2011-06-10 2018-10-10 MedImmune Limited Anti-pseudomonas psl binding molecules and uses thereof
WO2018187613A2 (en) 2017-04-07 2018-10-11 Bristol-Myers Squibb Company Anti-icos agonist antibodies and uses thereof
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018195527A1 (en) 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018200430A1 (en) 2017-04-26 2018-11-01 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
WO2018204895A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
WO2018209194A2 (en) 2017-05-12 2018-11-15 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
WO2019003104A1 (en) 2017-06-28 2019-01-03 Novartis Ag Methods for preventing and treating urinary incontinence
WO2019003165A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. Anti-fam19a5 antibodies and uses thereof
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. B7-h4 antibodies and methods of use thereof
WO2019048489A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh Antibodies useful in cancer diagnosis
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Human antibodies to thomsen-nouvelle (tn) antigen
WO2019087115A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2019087094A1 (en) 2017-11-03 2019-05-09 Novartis Ag Anti-cd40 antibodies for use in treatment of sjögren's syndrome
WO2019099440A1 (en) 2017-11-14 2019-05-23 Arcellx, Inc. Multifunctional immune cell therapies
WO2019099433A2 (en) 2017-11-14 2019-05-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
US10335485B2 (en) 2010-04-16 2019-07-02 Biogen Ma Inc. Anti-VLA-4 antibodies
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US10351617B2 (en) 2010-08-13 2019-07-16 Trustees Of Tufts College Compositions, kits and methods for treatment of complement-related disorders
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019147152A1 (en) 2018-01-26 2019-08-01 Universidade Nova De Lisboa L2a5 antibody or functional fragment thereof against tumour antigens
WO2019157447A1 (en) 2018-02-12 2019-08-15 Trustees Of Tufts College Cd59 for inhibiting inflammasome activation
WO2019169212A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
WO2019198019A1 (en) 2018-04-13 2019-10-17 Novartis Ag Anti-cd40 antibodies for use in prevention of graft rejection
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US10465011B2 (en) 2015-06-26 2019-11-05 Novartis Ag Factor XI antibodies and methods of use
WO2019214624A1 (en) 2018-05-11 2019-11-14 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing same, and use thereof
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP3575326A1 (en) 2012-12-17 2019-12-04 Trillium Therapeutics Inc. Treatment of cd47+ disease cells with sirp alpha-fc fusions
EP3575794A1 (en) 2012-02-10 2019-12-04 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
WO2020003172A1 (en) 2018-06-26 2020-01-02 Mor Research Applications Transthyretin antibodies and uses thereof
US10557125B2 (en) 2014-10-23 2020-02-11 Sanofi Selection marker for cell transfection and protein production
US10604568B2 (en) 2013-07-31 2020-03-31 BioN Tech AG Diagnosis and therapy of cancer involving cancer stem cells
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
US10647780B2 (en) 2016-05-25 2020-05-12 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
WO2020109978A1 (en) 2018-11-26 2020-06-04 Novartis Ag Lpl-gpihbp1 fusion polypeptides
EP3670537A1 (en) 2013-03-18 2020-06-24 Astellas Pharma Inc. Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
WO2020144605A1 (en) 2019-01-11 2020-07-16 Novartis Ag Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
EP3683239A1 (en) 2019-01-17 2020-07-22 Beijing Mabworks Biotech Co. Ltd. Antibodies binding human claudin 18.2 and uses thereof
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
WO2020167912A1 (en) 2019-02-13 2020-08-20 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
WO2020176497A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
WO2020188021A1 (en) 2019-03-19 2020-09-24 Sanofi Novel selection marker-comprising cell line and uses thereof for protein production
EP3725810A1 (en) 2012-05-23 2020-10-21 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3733701A1 (en) 2015-03-31 2020-11-04 MedImmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
EP3736293A1 (en) 2013-02-12 2020-11-11 Boehringer Ingelheim International Gmbh Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2020225736A1 (en) 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
EP3738611A1 (en) 2013-07-31 2020-11-18 BioNTech AG Diagnosis and therapy of cancer involving cancer stem cells
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
WO2020250159A1 (en) 2019-06-12 2020-12-17 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US10894818B2 (en) 2014-10-03 2021-01-19 Massachusetts Institute Of Technology Antibodies that bind Ebola glycoprotein and uses thereof
EP3766903A2 (en) 2012-11-13 2021-01-20 BioNTech SE Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
WO2021025177A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021030488A1 (en) 2019-08-12 2021-02-18 Bienvenue David Leonard 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
EP3792278A2 (en) 2012-12-21 2021-03-17 Biogen MA Inc. Human anti-tau antibodies
WO2021048595A1 (en) 2019-09-11 2021-03-18 Novartis Ag A method for preventing human virus associated disorders in patients
WO2021058563A1 (en) 2019-09-23 2021-04-01 King's College London Dap10/dap12 fusion polypeptides
WO2021058472A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
WO2021079002A2 (en) 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
US11008389B2 (en) 2011-03-16 2021-05-18 Sanofi Uses of a dual V region antibody-like protein
WO2021138264A1 (en) 2019-12-30 2021-07-08 Seagen Inc. Methods of treating cancer with nonfucosylated anti-cd70 antibodies
WO2021167964A1 (en) 2020-02-18 2021-08-26 Alector Llc Pilra antibodies and methods of use thereof
WO2021170020A1 (en) 2020-02-27 2021-09-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
WO2021176042A1 (en) 2020-03-06 2021-09-10 King's College London Therapeutic agents
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
WO2021228091A1 (en) 2020-05-12 2021-11-18 正大天晴药业集团股份有限公司 St2 antigen binding protein
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021234163A1 (en) 2020-05-22 2021-11-25 King's College London Chimeric nkg2d protein
WO2021233834A1 (en) 2020-05-17 2021-11-25 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of selecting and using the same
WO2021245184A1 (en) 2020-06-02 2021-12-09 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
EP3925978A1 (en) 2011-06-13 2021-12-22 AltruBio Inc. Anti-psgl-1 antibodies and uses thereof
EP3935183A1 (en) 2019-03-04 2022-01-12 Beijing Mabworks Biotech Co. Ltd. Antibodies binding cd40 and uses thereof
WO2022018040A2 (en) 2020-07-20 2022-01-27 Astrazeneca Uk Limited Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
US11242395B2 (en) 2017-08-21 2022-02-08 Adagene Inc. Anti-CD137 molecules and use thereof
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
WO2022040345A1 (en) 2020-08-18 2022-02-24 Cephalon, Inc. Anti-par-2 antibodies and methods of use thereof
WO2022051549A1 (en) 2020-09-04 2022-03-10 Rutgers, The State University Of New Jersey Sars-cov-2 vaccines and antibodies
WO2022058603A1 (en) 2020-09-21 2022-03-24 Sanofi Generation of a high producing recombinant chinese hamster ovary cell line for therapeutic protein production
WO2022081779A1 (en) 2020-10-13 2022-04-21 Avitide LLC Affinity ligand libraries of three-helix bundle proteins and uses thereof
WO2022081775A1 (en) 2020-10-13 2022-04-21 Avitide LLC Aav8 affinity agents
US11319526B2 (en) 2008-05-02 2022-05-03 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
WO2022101358A1 (en) 2020-11-11 2022-05-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2022119976A1 (en) 2020-12-01 2022-06-09 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
US11359016B2 (en) 2018-02-02 2022-06-14 Adagene Inc. Anti-CTLA4 antibodies and methods of making and using the same
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
WO2022144406A1 (en) 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
WO2022143670A1 (en) 2020-12-30 2022-07-07 和铂医药(苏州)有限公司 Antibody capable of binding to trop2, and use thereof
WO2022178396A1 (en) 2021-02-19 2022-08-25 Avitide LLC Aav2 affinity agents
WO2022203090A1 (en) 2021-03-25 2022-09-29 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2022200498A1 (en) 2021-03-26 2022-09-29 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
WO2022200442A1 (en) 2021-03-23 2022-09-29 King's College London Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022217019A1 (en) 2021-04-09 2022-10-13 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
EP4085076A1 (en) 2020-01-03 2022-11-09 Biosion, Inc. Antibodies binding bcma and uses thereof
WO2022262959A1 (en) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
WO2022262828A1 (en) 2021-06-18 2022-12-22 正大天晴药业集团股份有限公司 Anti-il-36r antibody and use thereof
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
US11613588B2 (en) 2017-06-28 2023-03-28 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2023064927A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable polypeptide complex
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
WO2023064929A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable polypeptide complex
EP4177273A1 (en) 2013-02-20 2023-05-10 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2023091865A1 (en) 2021-11-08 2023-05-25 Celldex Therapeutics, Inc. Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023093816A1 (en) 2021-11-25 2023-06-01 诺纳生物（苏州）有限公司 Anti-siglec-15 antibody and use thereof
WO2023111095A2 (en) 2021-12-15 2023-06-22 King's College London Engineered immune cell
WO2023122327A2 (en) 2021-12-24 2023-06-29 Avitide LLC Chi domain affinity ligands and agents
WO2023152382A1 (en) 2022-02-14 2023-08-17 King's College London Artificial microrna construct
EP4249066A2 (en) 2014-12-23 2023-09-27 Bristol-Myers Squibb Company Antibodies to tigit
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
WO2023193817A1 (en) 2022-04-08 2023-10-12 Adagene Pte. Ltd. Anti-cd28 antibodies and methods of use thereof
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
EP4271712A1 (en) 2020-12-30 2023-11-08 Immunomic Therapeutics, Inc. Anti-hvem antibodies
WO2023217987A1 (en) 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023242362A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/antigen-binding molecules and methods of use
US11873333B2 (en) 2020-12-11 2024-01-16 The University Of North Carolina At Chapel Hill Compositions and methods comprising SFRP2 antagonists
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024025911A1 (en) 2022-07-29 2024-02-01 Avitide LLC An affinity agent comprising a ligand that binds vce and comprises seq id no: 1
WO2024038187A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Assay for detection of il-33
WO2024054656A2 (en) 2022-09-09 2024-03-14 Avitide LLC Affinity agents
US11952681B2 (en) 2018-02-02 2024-04-09 Adagene Inc. Masked activatable CD137 antibodies
US11970532B2 (en) 2018-05-10 2024-04-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
US12030927B2 (en) 2022-02-18 2024-07-09 Rq Biotechnology Limited Antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
EP4406549A2 (en) 2014-07-29 2024-07-31 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
WO2024231440A1 (en) 2023-05-09 2024-11-14 Astrazeneca Ab Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof
WO2024235175A1 (en) 2023-05-12 2024-11-21 智泽童康(广州)生物科技有限公司 Anti-cldn6 antibody and use thereof
US12162952B2 (en) 2018-04-27 2024-12-10 Neurimmune Ag Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibody
US12216120B2 (en) 2020-03-26 2025-02-04 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
EP4530295A2 (en) 2023-09-07 2025-04-02 argenx BV Fcrn antagonists and methods of use
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025083173A1 (en) 2023-10-17 2025-04-24 Linnane Pharma Ab Bacterial lon protease domains and their use in therapy
WO2025082594A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025083076A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
EP4545566A2 (en) 2020-02-28 2025-04-30 The Brigham and Women's Hospital Inc. SELECTIVE MODULATION OF TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY SIGNALING VIA MULTISPECIFIC ANTIBODIES
WO2025104253A1 (en) 2023-11-17 2025-05-22 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
EP4559477A2 (en) 2020-05-13 2025-05-28 Adagene AG Compositions and methods for treating cancer
US12324841B2 (en) 2018-05-07 2025-06-10 Genmab A/S Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2025133694A1 (en) 2023-12-20 2025-06-26 argenx BV Fcrn/hsa-binding molecules and methods of use
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025133186A1 (en) 2023-12-22 2025-06-26 OncoC4, Inc. Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies
WO2025157132A1 (en) 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
EP4596575A2 (en) 2021-03-26 2025-08-06 Arcellx, Inc. Multifunctional immune cell therapies
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025191498A1 (en) 2024-03-12 2025-09-18 Adaptam Therapeutics, S.L. Anti-siglec-15 antibodies and uses thereof
WO2025196207A1 (en) 2024-03-20 2025-09-25 King's College London Compositions and methods for use in depleting senescent cells and treating aging
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
US12435145B2 (en) 2018-02-21 2025-10-07 Five Prime Therapeutics, Inc. B7-H4 antibody formulations
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
US12492244B2 (en) 2019-01-02 2025-12-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2025261951A1 (en) 2024-06-18 2025-12-26 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
US12540193B2 (en) 2019-05-31 2026-02-03 Trustees Of Tufts College Anti-ADAM8 antibodies and uses of the same
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
US12558421B2 (en) 2016-08-17 2026-02-24 Compugen Ltd. Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies
WO2026041780A2 (en) 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment
WO2026057739A1 (en) 2024-09-12 2026-03-19 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment
WO2026057545A1 (en) 2024-09-10 2026-03-19 Neurimmune Ag Anti-sting antibodies and methods of use thereof

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
GB9415319D0 (en) * 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
DK1141028T3 (en) 1998-12-23 2010-05-25 Pfizer Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
NZ519655A (en) * 1999-12-21 2004-04-30 Merial Sas Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20020099183A1 (en) * 2000-08-23 2002-07-25 Pluschkell Stefanie Beate Process for the preparation of neutrophil inhibitory factor
BRPI0116728B1 (en) 2001-01-05 2018-10-30 Pfizer Inc. insulin-like growth factor i receptor antibodies
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7176300B2 (en) * 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
WO2002079447A2 (en) 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) * 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
WO2002079470A1 (en) * 2001-03-30 2002-10-10 King A Christie Disease-specific promoter chimeras for gene expression
WO2002092017A2 (en) 2001-05-16 2002-11-21 Albert Einstein College Of Medicine Of Yeshiva University Human antipneumococcal antibodies from non-human animals
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US7550650B2 (en) * 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US20100333219A1 (en) * 2001-11-30 2010-12-30 Synageva Biopharma Corp. Methods of protein production using ovomucoid regulatory regions
US7335761B2 (en) * 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) * 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
US20040241723A1 (en) * 2002-03-18 2004-12-02 Marquess Foley Leigh Shaw Systems and methods for improving protein and milk production of dairy herds
BR0309254A (en) 2002-04-12 2005-03-01 Medarex Inc Use of an anti-ctla-4 antibody
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
PT1534736E (en) 2002-08-10 2010-09-07 Univ Yale Nogo receptor antagonists
SI2301965T1 (en) 2002-10-16 2015-07-31 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
DK1585546T3 (en) 2002-12-30 2008-12-08 Biogen Idec Inc KIM- 1- Antagonists and Use to Modulate Immune System
CN1980571A (en) * 2003-01-24 2007-06-13 阿维季尼克斯股份有限公司 Foreign proteins expressed in poultry and poultry eggs
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
WO2005035771A2 (en) 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Nucleic acid constructs
EP1844815B1 (en) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
EP1680141B8 (en) 2003-11-04 2011-01-12 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
CA2544951A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
PT1694360E (en) 2003-11-04 2010-12-13 Novartis Vaccines & Diagnostic Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
MX350383B (en) 2004-01-09 2017-09-04 Pfizer ANTIBODIES AGAINST MADCAM.
MXPA06009452A (en) 2004-02-19 2007-03-15 Univ Alberta Leptin promoter polymorphisms and uses thereof.
KR20070036130A (en) 2004-07-16 2007-04-02 화이자 프로덕츠 인코포레이티드 Combination therapy for non-hematologic malignancies using anti-IGF-1AL antibody
PL1781321T3 (en) 2004-08-02 2014-07-31 Zenyth Operations Pty Ltd A method of treating cancer comprising a vegf-b antagonist
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP2008518629A (en) 2004-11-08 2008-06-05 シェーリング コーポレイション Association of MDL-1 with tumor and method thereof
WO2006060769A2 (en) * 2004-12-03 2006-06-08 Xoma Technology Ltd. Methods and materials for expression of a recombinant protein
GB0504587D0 (en) * 2005-03-05 2005-04-13 Ml Lab Plc Vectors comprising guinea pig CMV regulatory elements
ES2330784T3 (en) * 2005-03-05 2009-12-15 Millipore Corporation VECTORS THAT UNDERSTAND NEW REGULATORY ELEMENTS.
EP1871806A2 (en) 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
EP3058955B1 (en) 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
NL1031674C2 (en) 2005-04-25 2007-04-26 Pfizer Antibodies to myostatin.
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
PE20061444A1 (en) 2005-05-19 2007-01-15 Centocor Inc ANTI-MCP-1 ANTIBODY, COMPOSITIONS, METHODS AND USES
CA2615460A1 (en) 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
CA2621371C (en) 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc Ctla-4 antibody dosage escalation regimens
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
KR20090029184A (en) 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Antibody Compositions and Methods of Treatment of Neoplastic Diseases
MX2008013508A (en) 2006-04-21 2008-10-31 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions.
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20080112888A1 (en) 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
EP2054444B1 (en) 2006-08-04 2016-11-02 MedImmune Limited Antibodies to erbb2
EP2526959B1 (en) 2006-08-11 2017-08-02 CSL Limited Treatment of pulmonary disease conditions
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CA2672828A1 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
AU2007345347B2 (en) * 2007-01-26 2013-11-07 Synageva Biopharma Corp Transgene expression in avians
SG178744A1 (en) 2007-02-02 2012-03-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
JP5357782B2 (en) 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド Regulation of NKT cell activity by antigen-loaded CD1d molecules
JP5330398B2 (en) 2007-10-26 2013-10-30 シーエスエル、リミテッド Cytokine mutein
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
WO2009073511A2 (en) * 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
CA2711499C (en) 2008-01-10 2018-09-25 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
US20100192236A1 (en) * 2009-01-28 2010-07-29 University Of South Carolina Modulation of Delta Opioid Receptor Expression
US20100284977A1 (en) * 2009-04-28 2010-11-11 University Of South Carolina Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
CN102762593B (en) 2009-07-31 2015-05-20 梅达雷克斯有限责任公司 Fully human antibodies to btla
TWI627281B (en) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 Methods of reducing viricidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity
PL2477656T3 (en) 2009-09-15 2017-09-29 Csl Limited Treatment of neurological conditions
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
DK2580243T3 (en) 2010-06-09 2020-01-13 Genmab As ANTIBODIES AGAINST HUMAN CD38
JP6055404B2 (en) 2010-06-15 2016-12-27 ゲンマブ エー／エス Human antibody drug conjugates against tissue factor
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
CA2809369A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc. Notum protein modulators and methods of use
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
AR083533A1 (en) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed PROTEINS OF HEMAGLUTININ 5 (H5) FOR THE TREATMENT AND PREVENTION OF INFLECTIONS OF FLU
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
HK1200329A1 (en) 2011-04-25 2015-08-07 先进生物学实验室股份有限公司 Truncated hiv envelope proteins (env), methods and compositions related thereto
SI2741740T1 (en) 2011-08-12 2017-08-31 Merial, Inc. Vacuum-assisted preservation of biological products, in particular of vaccines
AR088028A1 (en) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed PROTEINS H5, FROM H5N1 FOR MEDICINAL USE
BR112014003315A2 (en) 2011-08-15 2017-03-01 Univ Chicago antibody-related compositions and methods for staphylococcal protein
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
ES2925654T3 (en) 2011-09-30 2022-10-19 Dana Farber Cancer Inst Inc Therapeutic peptides comprising antibodies that bind to MHC class I polypeptide-related A sequence (MICA)
RU2014114015A (en) 2011-11-08 2015-12-20 Пфайзер Инк. METHODS FOR TREATING INFLAMMATORY DISORDERS USING ANTIBODIES AGAINST M-CSF
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
DK2711426T3 (en) 2012-09-24 2015-07-13 Lonza Biologics Plc Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
CA2891388C (en) 2012-11-20 2021-09-14 Novartis Ag Optimized expression cassette for expressing a polypeptide with high yield
JP6396313B2 (en) 2012-12-07 2018-09-26 ファイザー・インク Engineered monomeric antibody fragments
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
EP2956169B1 (en) 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoclonal antibodies that neutralize norovirus
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
KR20150130462A (en) 2013-03-15 2015-11-23 다나-파버 캔서 인스티튜트 인크. Therapeutic peptides
WO2014144666A2 (en) 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
EP2981821B2 (en) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
EP3583950A1 (en) 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
PH12021552742A1 (en) 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
EA201691078A1 (en) 2013-12-06 2017-01-30 Дана-Фарбер Кэнсер Инститьют, Инк. THERAPEUTIC PEPTIDES
JP6701079B2 (en) 2013-12-20 2020-05-27 インターベット インターナショナル ベー． フェー． Canine mouse antibody against human PD-1
CN104805107B (en) * 2014-01-26 2018-03-23 中国人民解放军军事医学科学院生物工程研究所 It is a kind of based on the zooblast efficient expression vector of GS screening systems and application
WO2015139020A2 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
EA201691993A1 (en) 2014-04-03 2017-02-28 Бёрингер Ингельхайм Ветмедика, Инк. VACCINE TO THE VIRUS EPIDEMIC DIARRHEA OF PIGS
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
ES2936810T3 (en) 2014-05-16 2023-03-22 Pfizer Bispecific antibodies with engineered CH1-CL interfaces
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
US10072070B2 (en) 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
DK3240801T3 (en) 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc COMBINATION TUMOR IMMUNERAPY
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CN113480640B (en) 2015-06-01 2024-07-30 免疫医疗有限责任公司 Neutralizing anti-influenza binding molecules and uses thereof
EA036116B1 (en) 2015-08-31 2020-09-30 Берингер Ингельхайм Ветмедика Гмбх Pestivirus vaccines for congenital tremors
AU2016323106A1 (en) 2015-09-16 2018-03-29 Boehringer Ingelheim Animal Health USA Inc. Salmonella Choleraesuis-Salmonella Typhimurium vaccines
PL3368572T3 (en) 2015-10-02 2022-09-12 Symphogen A/S Anti-pd-1 antibodies and compositions
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme An antibody that inactivates the human pneumonia virus
CR20180279A (en) 2015-11-18 2018-08-24 Merck Sharp & Dohme CTLA4 BINDERS
US10544222B2 (en) 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
MA43260A (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme BINDERS PD1 AND / OR LAG3
US20170145103A1 (en) 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
SG11201804648RA (en) 2015-12-04 2018-06-28 Univ Texas Slc45a2 peptides for immunotherapy
KR20180086502A (en) 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 The anti-LAG3 antibody and the antigen-binding fragment
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
TN2018000333A1 (en) 2016-04-12 2020-01-16 Symphogen As Anti-tim-3 antibodies and compositions
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
KR102543878B1 (en) 2016-08-23 2023-06-14 메디뮨 리미티드 Anti-VEF-A and Anti-ANG2 Antibodies and Uses Thereof
KR102538827B1 (en) 2016-08-23 2023-05-31 메디뮨 리미티드 Anti-VEF-A Antibodies and Uses Thereof
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
KR102618843B1 (en) 2016-09-20 2024-01-02 베링거잉겔하임베트메디카게엠베하 Novel EHV insertion site ORF70
WO2018057441A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
WO2018054822A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
MY199909A (en) 2016-09-20 2023-11-29 Boehringer Ingelheim Vetmedica Gmbh Promoters
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
MY203971A (en) 2016-10-13 2024-07-26 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
AU2017353380B2 (en) 2016-11-03 2024-08-22 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
MX381132B (en) 2016-11-03 2025-03-12 Boehringer Ingelheim Vetmedica Gmbh PORCINE PARVOVIRUS VACCINE.
TWI780083B (en) 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 Anti-pd-1 antibodies and compositions
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
CN110545841A (en) 2017-01-30 2019-12-06 勃林格殷格翰动物保健美国有限公司 Porcine coronavirus vaccine
EA201992350A1 (en) 2017-04-05 2020-03-23 Симфоген А/С COMBINED MEDICINES AIMED AT PD-1, TIM-3 AND LAG-3
RU2665790C1 (en) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Monoclonal pd-l1 antibody
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2019014144A1 (en) 2017-07-12 2019-01-17 Boehringer Ingelheim Vetmedica, Inc. Senecavirus a immunogenic compositions and methods thereof
CN111032694B (en) 2017-07-14 2024-03-08 辉瑞大药厂 Antibodies against MADCAM
TW201923084A (en) 2017-09-23 2019-06-16 德商百靈佳殷格翰維美迪加股份有限公司 PARAMYXOVIRIDAE expression system
RU2698048C2 (en) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" Monoclonal antibody to il-5rα
EA039662B1 (en) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Antibodies specific to cd47 and pd-l1
CN119930795A (en) 2017-10-12 2025-05-06 得克萨斯大学体系董事会 T cell receptors for immunotherapy
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
EA202091958A1 (en) 2018-02-23 2021-02-04 Бёрингер Ингельхайм Ветмедика Гмбх RECOMBINANT VIRAL VECTOR SYSTEMS EXPRESSING EXOGENIC GENES OF FIT PARAMIXOVIRUS AND VACCINES PREPARED FROM THEM
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
CN111867637B (en) 2018-03-19 2024-05-03 勃林格殷格翰动物保健有限公司 Novel EHV insertion site UL43
EA202092164A1 (en) 2018-03-19 2021-02-10 Бёрингер Ингельхайм Ветмедика Гмбх NEW EHV WITH INACTIVATED UL18 AND / OR UL8
MX420109B (en) 2018-03-26 2025-02-10 Boehringer Ingelheim Animal Health Usa Inc Method of producing an immunogenic composition
KR102890791B1 (en) 2018-04-09 2025-11-24 체크메이트 파마슈티칼스, 인크. Packaging of oligonucleotides into virus-like particles
WO2019217457A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
US20210196834A1 (en) 2018-05-30 2021-07-01 Abbvie Stemcentrx Llc Anti-sez6 antibody drug conjugates and methods of use
RU2706298C1 (en) 2018-09-14 2019-11-15 Закрытое Акционерное Общество "Биокад" PaCas9 NUCLEASE
CN112867506B (en) 2018-09-20 2025-08-05 勃林格殷格翰动物保健有限公司 Intranasal vectored vaccine against porcine epidemic diarrhea
JP7284822B2 (en) 2018-09-20 2023-05-31 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Modified PEDV spike protein
RU2724469C2 (en) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds to cd20
WO2020163225A1 (en) 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anti-cd228 antibodies and antibody-drug conjugates
RU2734432C1 (en) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds gitr
AU2020300002A1 (en) 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
CN114174337B (en) 2019-07-15 2024-10-25 英特维特国际股份有限公司 Caninized antibody against canine CTLA-4
CA3145347A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
RU2753282C2 (en) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION
AU2020358859A1 (en) 2019-10-04 2022-05-12 Seagen Inc. Anti-PD-L1 antibodies and antibody-drug conjugates
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
AU2020379001A1 (en) 2019-11-04 2022-06-09 Paul RUBINSTEIN Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection
TW202131954A (en) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
MX2022005222A (en) 2019-11-07 2022-06-08 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate.
US20230053131A1 (en) 2019-12-20 2023-02-16 Intervet Inc. Antibodies to canine interleukin-4 receptor alpha
MX2022007636A (en) 2019-12-20 2022-07-19 Intervet Int Bv CANINIZED BISPECIFIC ANTIBODIES AND BISPECIFIC BINDING PAIRS FOR THE TREATMENT AGAINST ATOPIC DERMATITIS.
CN115768784A (en) 2020-02-06 2023-03-07 勃林格殷格翰动物保健有限公司 Peptides for the detection of anti-rhabdovirus antibodies
EP4143227A2 (en) 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antibodies
EP3909601A1 (en) 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
RU2742837C1 (en) 2020-06-02 2021-02-11 Общество С Ограниченной Ответственностью "Анабион" Codon-optimized nucleic acid which encodes smn1 protein, and use thereof
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
MX2022015375A (en) 2020-06-29 2023-01-16 Genmab As Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer.
IT202000015754A1 (en) 2020-06-30 2021-12-30 Fond Toscana Life Sciences ANTIBODIES TO CORONAVIRUS
EP4175982A1 (en) 2020-06-30 2023-05-10 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
MX2023001055A (en) 2020-07-24 2023-03-17 Amgen Inc Immunogens derived from sars-cov2 spike protein.
KR20230042518A (en) 2020-08-04 2023-03-28 씨젠 인크. Anti-CD228 Antibodies and Antibody-Drug Conjugates
US20220160864A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
CN116438195A (en) 2020-10-05 2023-07-14 勃林格殷格翰动物保健有限公司 Fusion proteins for vaccination against rotavirus
AU2021359068A1 (en) 2020-10-15 2023-06-15 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
WO2022108931A2 (en) 2020-11-17 2022-05-27 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
AR126840A1 (en) 2021-08-20 2023-11-22 Llc «Anabion» MODIFIED VP1 CAPSID PROTEIN ISOLATED FROM ADENO-ASSOCIATED VIRUS SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED ON THIS
MX2024002149A (en) 2021-08-20 2024-03-08 Intervet Int Bv Fusion proteins for treating atopic dermatitis.
AR126839A1 (en) 2021-08-20 2023-11-22 Llc «Anabion» MODIFIED VP1 CAPSID PROTEIN ISOLATED FROM ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED ON THIS
MX2024002150A (en) 2021-08-20 2024-03-08 Intervet Int Bv ANTIBODIES AND IGG FUSION PROTEINS WITH A LONG HALF-LIFE.
IL310949A (en) 2021-08-20 2024-04-01 Biocad Joint Stock Co Method for producing modified adeno-associated virus capsid
WO2023059112A1 (en) * 2021-10-06 2023-04-13 주식회사 지앤피바이오사이언스 Development of optimal recombinant expression construct
TW202332694A (en) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 Serum half-life extended pd-l1 binding polypeptides
TW202334196A (en) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1 binding polypeptides
IL312110A (en) 2021-10-29 2024-06-01 Seagen Inc Cancer treatment methods with a combination of anti-PD-1 antibody and antibody-CD30 conjugate
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
EP4448571A1 (en) 2021-12-16 2024-10-23 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha ii
WO2023111157A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized and felinized antibodies to human ngf
WO2023153876A1 (en) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Stefin a protein variants specifically binding to cd40l, and uses thereof
CA3260121A1 (en) 2022-03-25 2023-09-28 Les Laboratoires Servier Anti-gal3 antibodies and compositions
KR20240170836A (en) 2022-04-05 2024-12-04 베링거잉겔하임베트메디카게엠베하 Immunogenic composition useful for vaccination against rotavirus
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
CN120435319A (en) 2022-11-03 2025-08-05 思进公司 Anti-AVB6 antibodies and antibody-drug conjugates and their use in cancer treatment
IT202300000924U1 (en) 2023-01-23 2024-12-22 Philomena Dove ALL-UP STITCHING SEAMLESS LEGGINGS
JP2026506599A (en) 2023-02-13 2026-02-25 インターベット インターナショナル ベー． フェー． Canine antibodies against canine IL-4
EP4665459A1 (en) 2023-02-13 2025-12-24 Intervet International B.V. Canine antibodies to canine il-13
EP4688825A1 (en) 2023-03-31 2026-02-11 AffyXell Therapeutics Co., Ltd. Tnfr2 binding polypeptides and methods of use
FR3147278A1 (en) 2023-03-31 2024-10-04 Avacta Life Sciences Limited TNFR2-BINDING POLYPEPTIDES AND METHODS OF USE
KR20260013515A (en) 2023-04-24 2026-01-28 머크 샤프 앤드 돔 엘엘씨 TROP2 binder and its conjugate
IL324556A (en) 2023-05-19 2026-01-01 Servier Lab Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
IT202300015579A1 (en) 2023-07-25 2025-01-25 Fond Toscana Life Sciences ANTIBODIES AGAINST COVID-19 AND OTHER HUMAN CORONAVIRUSES
WO2025038362A1 (en) 2023-08-11 2025-02-20 Merck Sharp & Dohme Llc Monovalent interleukin 12 (il-12) heterodimeric fc proteins
WO2025046393A1 (en) 2023-08-25 2025-03-06 Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) Reagents against human endogenous retroviruses to target cancer cells
IT202300026115A1 (en) 2023-12-06 2025-06-06 Fond Per L’Istituto Oncologico Di Ricerca Ior An Antibody-Based Strategy Targeting Activated Oncogenic ERG in Prostate Cancer
TW202545567A (en) 2024-01-30 2025-12-01 美商思進公司 Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
EP4635983A1 (en) 2024-04-15 2025-10-22 Ymmunobio AG A novel antibody binding specifically to nptxr and use thereof
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552A1 (en) * 1984-08-24 1986-03-05 The Upjohn Company Recombinant DNA compounds and the expression of polypeptides such as tPA
EP0260148A2 (en) * 1986-09-12 1988-03-16 Genentech, Inc. Improved recombinant expression method, vector and transformed cells
EP0173177B1 (en) * 1984-08-24 1992-04-22 BEHRINGWERKE Aktiengesellschaft Enhancer for eukaryotic expression systems

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552A1 (en) * 1984-08-24 1986-03-05 The Upjohn Company Recombinant DNA compounds and the expression of polypeptides such as tPA
EP0173177B1 (en) * 1984-08-24 1992-04-22 BEHRINGWERKE Aktiengesellschaft Enhancer for eukaryotic expression systems
EP0260148A2 (en) * 1986-09-12 1988-03-16 Genentech, Inc. Improved recombinant expression method, vector and transformed cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gene, vol. 38, no. 1/3, 1985 Elsevier Biomedical Press, (Amsterdam, NL) F. Pasleau et al.: "Growth hormone gene expression in eukaryotic cells directed by the Rous sarcoma virus long terminal repeat or cytomegalovirus immediate-early promotor", pages 227-232 *
Journal of Virology, vol. 56, no. 1, October 1985 American Society for Microbiology (US) R.R. Speate et al.: "Regulation of cytomegalovirus gene expression: a and b promoters are trans activated by viral functions in permissive human fibroblasts", pages 135-143 *

Cited By (853)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396083B1 (en) * 1989-05-01 1994-11-30 Schering Corporation Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use
WO1991009118A3 (en) * 1989-12-07 1991-10-31 British Bio Technology Activatable fibrinolytic and anti-thrombotic proteins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
WO1993023542A1 (en) 1992-05-08 1993-11-25 The Biotechnology And Biological Sciences Research Recombinant dna molecules encoding aminopeptidase enzymes and their use in the preparation of vaccines against helminth infections
US8226950B2 (en) 1993-01-12 2012-07-24 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
US7829092B2 (en) 1993-01-12 2010-11-09 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
US7482003B2 (en) 1993-01-12 2009-01-27 Biogen Idec Ma Inc. Treatment for asthma with α4-specific antibodies
US6602503B1 (en) 1993-01-12 2003-08-05 Biogen, Inc. Recombinant anti-VLA-4 antibody molecules
US7157086B2 (en) 1993-01-12 2007-01-02 Biogen Idec Ma Inc. Treatment for inflammatory bowel disease with α4-specific antibodies
US6150339A (en) * 1993-04-23 2000-11-21 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
US6355785B1 (en) * 1993-04-23 2002-03-12 Aronex Pharmaceuticals, Inc. Guanosine-rich oligonucleotide integrase inhibitors
US6184369B1 (en) * 1993-04-23 2001-02-06 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
US6288042B1 (en) 1993-04-23 2001-09-11 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
US6323185B1 (en) * 1993-04-23 2001-11-27 The United States Of America As Represented By The Department Of Health And Human Services Anti-viral guanosine-rich oligonucleotides and method of treating HIV
WO1995011982A1 (en) * 1993-10-25 1995-05-04 Menarini Ricerche Sud S.P.A. Expression system for eukaryotic cell lines
EP2364994A1 (en) 1994-01-05 2011-09-14 Schering Corporation Purfied primate CTLA-8 antigens and related reagents
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US6399588B1 (en) 1994-11-28 2002-06-04 Vical Incorporated Cancer treatment method utilizing plasmids suitable for IL-2 expression
US6147055A (en) * 1994-11-28 2000-11-14 Vical Incorporated Cancer treatment method utilizing plasmids suitable for IL-2 expression
EP1433855A3 (en) * 1994-11-28 2004-11-17 Vical Incorporated Plasmids suitable for il-2 expression
WO1996017063A1 (en) * 1994-11-28 1996-06-06 Vical Incorporated Plasmids suitable for il-2 expression
US7824675B2 (en) 1995-04-27 2010-11-02 Human Genome Sciences, Inc. Use of an antibody that binds human tumor necrosis factor receptor-like 2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
WO1997003997A1 (en) * 1995-07-19 1997-02-06 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
US8937169B2 (en) 1996-01-11 2015-01-20 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997045535A1 (en) * 1996-05-24 1997-12-04 Novartis Ag Recombinant rna 3'-terminal phosphate cyclases and production methods thereof
WO1998033807A1 (en) * 1997-02-04 1998-08-06 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
WO1999003981A1 (en) * 1997-07-17 1999-01-28 Ppl Therapeutics (Scotland) Limited Nucleic acid expression constructs incorporating a heterologous intron whose natural position is within the 5'untranslated region of its gene
WO2000023592A3 (en) * 1998-10-19 2000-07-27 Powderject Vaccines Inc Minimal promoters and uses thereof
EP1147205A4 (en) * 1998-12-31 2003-01-08 Viromed Ltd High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site
CN100368550C (en) * 1998-12-31 2008-02-13 瓦尔欧姆德有限公司 High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site
US7279568B2 (en) 1998-12-31 2007-10-09 Viromed Limited Highly efficient eukaryotic expression vector comprising an exogenous transcription regulatory element
EP2341144A1 (en) 1999-01-11 2011-07-06 Schering Corporation Interleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP2295456A1 (en) 2000-04-12 2011-03-16 Human Genome Sciences, Inc. Albumin fusion proteins
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
EP2236152A1 (en) 2000-04-12 2010-10-06 Human Genome Sciences, Inc. Albumin fusion proteins
EP2216409A1 (en) 2000-04-12 2010-08-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP2298355A2 (en) 2000-04-12 2011-03-23 Human Genome Sciences, Inc. Albumin fusion proteins
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
EP2357008A1 (en) 2000-04-12 2011-08-17 Human Genome Sciences, Inc. Albumin fusion proteins
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
EP2311872A1 (en) 2000-04-12 2011-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US8221983B2 (en) 2000-06-02 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP2431054A2 (en) 2000-06-15 2012-03-21 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP2281842A1 (en) 2000-06-16 2011-02-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
EP2281843A1 (en) 2000-06-16 2011-02-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
EP2275449A1 (en) 2000-06-16 2011-01-19 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7074590B2 (en) 2000-06-23 2006-07-11 Maxygen, Inc. Chimeric promoters
EP2338512A1 (en) 2000-11-28 2011-06-29 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2002043660A2 (en) 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
EP2027874A2 (en) 2000-11-28 2009-02-25 Medimmune, Inc. Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
EP2412384A1 (en) 2000-11-28 2012-02-01 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP2341060A1 (en) 2000-12-12 2011-07-06 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP2354149A1 (en) 2000-12-12 2011-08-10 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP3569610A2 (en) 2000-12-12 2019-11-20 Medlmmune, LLC Molecules with extended half lives, compositions and uses thereof
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
EP2228389A2 (en) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
US7423116B2 (en) 2001-04-30 2008-09-09 Seattle Genetics Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP2080766A1 (en) 2001-06-06 2009-07-22 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides useful for immunomodulation
EP2261250A1 (en) 2001-12-21 2010-12-15 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277888A2 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277889A2 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
EP2075346A2 (en) 2002-01-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Gene products differentially expressed in cancerous breast cells and their methods of use
US7473534B2 (en) 2002-03-01 2009-01-06 Siemens Healthcare Diagnostics Inc. Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples
US7732159B2 (en) 2002-03-01 2010-06-08 Siemens Healthcare Diagnostics Inc. Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
EP1961428A1 (en) 2002-04-02 2008-08-27 Ucb S.A. SC6 antibody for treatment of cancer
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
EP2270049A2 (en) 2002-04-12 2011-01-05 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
EP2570432A1 (en) 2002-06-14 2013-03-20 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP2353611A2 (en) 2002-07-31 2011-08-10 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP2357006A2 (en) 2002-07-31 2011-08-17 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP2158917A1 (en) 2002-09-19 2010-03-03 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services P.ariasi polypeptides, P.perniciosus polypeptides and methods of use
EP2316856A1 (en) 2002-10-17 2011-05-04 Genmab A/S Human monoclonal antibodies against CD20
EP3284753A2 (en) 2002-10-17 2018-02-21 Genmab A/S Human monoclonal antibodies against cd20
EP2330130A1 (en) 2002-10-17 2011-06-08 Genmab A/S Human monoclonal antibodies against CD20
EP2085467A2 (en) 2002-10-29 2009-08-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia Longipalpis polypeptides and methods of use
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US7259002B2 (en) 2003-01-21 2007-08-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
US7494805B2 (en) 2003-02-14 2009-02-24 Biogen Idec Ma Inc. Expression cassette and vector for transient or stable expression of exogenous molecules
EP1594955A4 (en) * 2003-02-14 2006-07-19 Biogen Idec Inc An expression cassette and vector for transient or stable expression of exogenous molecules
WO2004073737A1 (en) 2003-02-19 2004-09-02 Merial Limited Vaccination or immunization using a prime-boost regimen against brsv, bhv-1, bvdv, bpi-3
EP2289559A1 (en) 2003-02-20 2011-03-02 Seattle Genetics, Inc. Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP2100619A1 (en) 2003-02-20 2009-09-16 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein
US8765662B2 (en) 2003-03-19 2014-07-01 Biogen Idec Ma Inc. NOGO receptor binding protein
US7785829B2 (en) 2003-03-19 2010-08-31 Biogen Idec Ma, Inc. Nogo receptor binding protein
EP2316487A1 (en) 2003-04-11 2011-05-04 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
EP2404615A1 (en) 2003-04-23 2012-01-11 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
WO2005085448A2 (en) 2003-05-01 2005-09-15 Merial Limited Canine ghrh gene, polypeptides and methdos of use
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US7393534B2 (en) 2003-07-15 2008-07-01 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
US8257714B2 (en) 2003-07-15 2012-09-04 Michigan State University Compositions and methods for immunotherapy of cancer and infectious diseases
EP2272566A2 (en) 2003-08-18 2011-01-12 MedImmune, LLC Humanisation of antibodies
EP2260858A2 (en) 2003-11-06 2010-12-15 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
EP3858387A1 (en) 2003-11-06 2021-08-04 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
EP2478912A1 (en) 2003-11-06 2012-07-25 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
EP3120861A1 (en) 2003-11-06 2017-01-25 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
EP2486933A1 (en) 2003-11-06 2012-08-15 Seattle Genetics, Inc. Monomethylvaline compounds conjugated with antibodies
EP2489364A1 (en) 2003-11-06 2012-08-22 Seattle Genetics, Inc. Monomethylvaline compounds onjugated to antibodies
EP2383295A1 (en) 2003-12-10 2011-11-02 Medarex, Inc. IP-10 antibodies and their uses
EP2418220A2 (en) 2003-12-10 2012-02-15 Medarex, Inc. Interferon alpha antibodies and their uses
EP2865687A1 (en) 2003-12-10 2015-04-29 E. R. Squibb & Sons, L.L.C. IP-10 antibodies and their uses
EP3718564A1 (en) 2003-12-23 2020-10-07 Genentech, Inc. Novel anti-il 13 antibodies and uses thereof
WO2005062972A2 (en) 2003-12-23 2005-07-14 Tanox, Inc. Treatment of cancer with novel anti-il 13 monoclonal antibodies
EP2332575A1 (en) 2003-12-23 2011-06-15 Genentech, Inc. Treatment of cancer with novel anti-IL 13 monoclonal antibodies
EP2805728A1 (en) 2003-12-23 2014-11-26 Genentech, Inc. Novel anti-IL 13 antibodies and uses thereof
EP2351584A1 (en) 2003-12-23 2011-08-03 Genentech, Inc. Novel anti-IL 13 antibodies and uses thereof
EP2857418A1 (en) 2004-02-06 2015-04-08 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
EP2270045A1 (en) 2004-02-06 2011-01-05 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005090564A1 (en) 2004-03-19 2005-09-29 Genomidea Inc. Gene promoting vascular endothelial cell growth
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
WO2005117967A2 (en) 2004-04-12 2005-12-15 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
EP2662390A1 (en) 2004-06-21 2013-11-13 Medarex, L.L.C. Interferon alpha receptor 1 antibodies and their uses
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
US9068992B2 (en) 2004-06-24 2015-06-30 Biogen Ma Inc. Screening methods for identifying Sp35 antagonists
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
EP2329714A1 (en) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Influence of TAJ in the neuronal functions
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
WO2006102095A2 (en) 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies
EP2567976A2 (en) 2005-03-23 2013-03-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2535355A2 (en) 2005-03-23 2012-12-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2551282A2 (en) 2005-03-23 2013-01-30 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP3312196A1 (en) 2005-03-23 2018-04-25 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP3153525A1 (en) 2005-03-23 2017-04-12 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
EP2198881A1 (en) 2005-04-25 2010-06-23 Merial Limited Nipah virus vaccines
EP2221316A1 (en) 2005-05-05 2010-08-25 Duke University Anti-CD19 antibody therapy for autoimmune disease
EP2439272A2 (en) 2005-05-09 2012-04-11 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP2439273A2 (en) 2005-05-09 2012-04-11 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP2161336A1 (en) 2005-05-09 2010-03-10 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP3530736A2 (en) 2005-05-09 2019-08-28 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP2418278A2 (en) 2005-05-09 2012-02-15 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
EP2982379A1 (en) 2005-07-01 2016-02-10 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP3498289A1 (en) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
EP2722051A1 (en) 2005-07-07 2014-04-23 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
US8551476B2 (en) 2005-07-08 2013-10-08 Biogen Idec Ma Inc. SP35 antibodies and uses thereof
EP2238986A2 (en) 2005-07-08 2010-10-13 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
EP2394661A1 (en) 2005-07-08 2011-12-14 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
EP2478917A1 (en) 2005-07-08 2012-07-25 Biogen Idec MA Inc. SP35 antibodies and uses thereof
US9066984B2 (en) 2005-07-08 2015-06-30 Biogen Ma Inc. Sp35 antibodies and uses thereof
US8975375B2 (en) 2005-09-12 2015-03-10 Ganymed Pharmaceuticals Ag Identification of tumor-associated antigens for diagnosis and therapy
US9919036B2 (en) 2005-09-12 2018-03-20 Ganymed Pharmaceuticals Ag Identification of tumor-associated antigens for diagnosis and therapy
WO2007038637A2 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
EP2500030A2 (en) 2005-11-04 2012-09-19 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
EP2998318A1 (en) 2005-11-04 2016-03-23 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
EP2510934A1 (en) 2005-11-04 2012-10-17 Biogen Idec MA Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
EP2186823A1 (en) 2005-11-14 2010-05-19 Merial Limited Gene therapy for renal failure
EP3536704A1 (en) 2005-11-14 2019-09-11 Boehringer Ingelheim Animal Health USA Inc. Gene therapy for renal failure
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer
EP3421498A1 (en) 2005-11-24 2019-01-02 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
EP2295469A2 (en) 2005-11-24 2011-03-16 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2311878A2 (en) 2005-11-24 2011-04-20 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
EP3656793A1 (en) 2005-11-24 2020-05-27 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
EP2311877A2 (en) 2005-11-24 2011-04-20 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US10017564B2 (en) 2005-11-24 2018-07-10 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
EP2311879A2 (en) 2005-11-24 2011-04-20 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP3312197A1 (en) 2005-11-24 2018-04-25 Ganymed Pharmaceuticals GmbH Monoclonal antibodies against claudin-18 for treatment of cancer
EP2567973A2 (en) 2005-11-28 2013-03-13 Zymogenetics, Inc. IL-21 antagonists
EP2805971A1 (en) 2005-11-28 2014-11-26 ZymoGenetics, Inc. IL-21 antagonists
EP2543384A2 (en) 2005-12-02 2013-01-09 Biogen Idec MA Inc. Treatment of conditions involving demyelination
WO2007067992A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
EP2377886A1 (en) 2005-12-12 2011-10-19 F. Hoffmann-La Roche AG Antibody glycosylation in the variable region
EP2526968A2 (en) 2006-01-27 2012-11-28 Biogen Idec MA Inc. Nogo receptor antagonists
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP3167900A1 (en) 2006-03-29 2017-05-17 Merial Limited Vaccine against streptococci
EP2759307A2 (en) 2006-03-29 2014-07-30 Merial Limited Vaccine against Streptococci
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
WO2007141280A2 (en) 2006-06-06 2007-12-13 Oxford Genome Sciences (Uk) Ltd Proteins
EP2375255A1 (en) 2006-06-06 2011-10-12 Oxford Biotherapeutics Ltd. Proteins
EP2671946A1 (en) 2006-06-30 2013-12-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008105797A2 (en) 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucleotides encoding novel pcsk9 variants
EP2639301A2 (en) 2006-06-30 2013-09-18 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
WO2008018641A1 (en) 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
EP2292663A2 (en) 2006-08-28 2011-03-09 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
EP2484696A1 (en) 2006-08-28 2012-08-08 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
WO2008030611A2 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
EP3753576A1 (en) 2006-09-26 2020-12-23 Genmab A/S Combination treatment of cd38-expressing tumors
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP2486941A1 (en) 2006-10-02 2012-08-15 Medarex, Inc. Human antibodies that bind CXCR4 and uses thereof
EP2407548A1 (en) 2006-10-16 2012-01-18 MedImmune, LLC Molecules with reduced half-lives, compositions and uses thereof
EP2829551A1 (en) 2006-10-19 2015-01-28 CSL Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
EP2530090A2 (en) 2006-10-19 2012-12-05 CSL Limited Anti-IL-13R alpha 1 antibodies and their uses thereof
EP2228071A1 (en) 2006-11-14 2010-09-15 Merial Limited Intra-vascular kidney gene therapy with plasmid encoding BMP-7
WO2008076560A2 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
WO2008070569A2 (en) 2006-12-01 2008-06-12 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
EP2609932A2 (en) 2006-12-01 2013-07-03 Seattle Genetics, Inc. Variant target binding agents and uses thereof
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
WO2009054863A2 (en) 2006-12-13 2009-04-30 Medarex, Inc. Human antibodies that bind cd19 and uses thereof
WO2008074004A2 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
EP2610267A1 (en) 2006-12-18 2013-07-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
EP3239174A1 (en) 2007-01-05 2017-11-01 University of Zurich Anti-beta-amyloid antibody and uses thereof
EP2426143A2 (en) 2007-01-05 2012-03-07 University of Zurich Method of providing disease-specific binding molecules and targets
EP3239175A1 (en) 2007-01-05 2017-11-01 University of Zurich Method of providing disease-specific binding molecules and targets
EP2436696A1 (en) 2007-01-05 2012-04-04 University of Zurich Method of providing disease-specific binding molecules and targets
EP2740744A2 (en) 2007-01-09 2014-06-11 Biogen Idec MA Inc. SP35 antibodies and uses thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8609407B2 (en) 2007-01-09 2013-12-17 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US8114606B2 (en) 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
WO2008108918A1 (en) 2007-02-21 2008-09-12 University Of Massachusetts Human antibodies against hepatitis c virus (hcv) uses thereof
EP2441775A1 (en) 2007-02-26 2012-04-18 Oxford Biotherapeutics Ltd. Protein
EP3118221A1 (en) 2007-02-26 2017-01-18 Oxford BioTherapeutics Ltd Proteins
EP3118220A1 (en) 2007-02-26 2017-01-18 Oxford BioTherapeutics Ltd Protein
EP2447719A1 (en) 2007-02-26 2012-05-02 Oxford Biotherapeutics Ltd. Proteins
US10125196B2 (en) 2007-03-14 2018-11-13 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US8354104B2 (en) 2007-03-14 2013-01-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
EP2487189A1 (en) 2007-03-14 2012-08-15 GANYMED Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9475867B2 (en) 2007-03-14 2016-10-25 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US8961980B2 (en) 2007-03-14 2015-02-24 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
EP2703007A1 (en) 2007-03-30 2014-03-05 MedImmune, LLC Antibodies with decreased deamidation profiles
EP2599791A1 (en) 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
EP3067368A1 (en) 2007-04-27 2016-09-14 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
WO2008136790A1 (en) 2007-05-02 2008-11-13 Merial Limited Dna plasmids having improved expression and stability
EP2703011A2 (en) 2007-05-07 2014-03-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2737907A2 (en) 2007-05-07 2014-06-04 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP3072525A1 (en) 2007-05-14 2016-09-28 MedImmune, LLC Methods of reducing basophil levels
WO2008145338A2 (en) 2007-05-29 2008-12-04 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
US9815902B2 (en) 2007-08-29 2017-11-14 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
US8647622B2 (en) 2007-08-29 2014-02-11 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US9243067B2 (en) 2007-08-29 2016-01-26 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US9228019B2 (en) 2007-08-29 2016-01-05 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US9175087B2 (en) 2007-08-29 2015-11-03 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US8980262B2 (en) 2007-08-29 2015-03-17 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US10098934B2 (en) 2007-09-04 2018-10-16 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US9555087B2 (en) 2007-09-04 2017-01-31 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US9107862B2 (en) 2007-09-04 2015-08-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2769729A1 (en) 2007-09-04 2014-08-27 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US9375466B2 (en) 2007-09-04 2016-06-28 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2009032845A2 (en) 2007-09-04 2009-03-12 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2769728A1 (en) 2007-09-04 2014-08-27 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2586796A1 (en) 2007-10-12 2013-05-01 Novartis AG Compositions and methods for use for antibodies against sclerostin
US9732162B2 (en) 2007-10-15 2017-08-15 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
US11453727B2 (en) 2007-10-15 2022-09-27 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
US8388965B2 (en) 2007-10-15 2013-03-05 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
US9738728B2 (en) 2007-10-15 2017-08-22 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2573121A1 (en) 2007-10-15 2013-03-27 Sanofi Antibodies that bind il-4 and/or il-13 and their uses
EP2573116A1 (en) 2007-10-15 2013-03-27 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2573118A1 (en) 2007-10-15 2013-03-27 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2574626A1 (en) 2007-10-15 2013-04-03 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2573117A1 (en) 2007-10-15 2013-03-27 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2574630A1 (en) 2007-10-15 2013-04-03 Sanofi Antibodies that bind il-4 and/or il-13 and their uses
EP2574629A1 (en) 2007-10-15 2013-04-03 Sanofi Antibodies that bind il-4 and/or il-13 and their uses
EP2573115A1 (en) 2007-10-15 2013-03-27 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
US10759871B2 (en) 2007-10-15 2020-09-01 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP3686220A1 (en) 2007-10-15 2020-07-29 Sanofi Antibodies that bind il-4 and/or il-13 and their uses
EP2573119A1 (en) 2007-10-15 2013-03-27 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
WO2009058322A1 (en) 2007-10-31 2009-05-07 Human Genome Sciences, Inc. Albumin fusion proteins
EP2567709A2 (en) 2007-11-02 2013-03-13 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
EP3305324A1 (en) 2007-11-02 2018-04-11 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
WO2009061818A1 (en) 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
EP2570137A2 (en) 2007-11-07 2013-03-20 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP3002298A1 (en) 2007-11-21 2016-04-06 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2010055366A2 (en) 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
EP2426146A2 (en) 2007-12-07 2012-03-07 ZymoGenetics, Inc. Anti-human IL-21 monoclonal antibodies
EP2769993A1 (en) 2007-12-14 2014-08-27 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
WO2009092011A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
US8653020B2 (en) 2008-01-25 2014-02-18 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
EP3260137A1 (en) 2008-01-28 2017-12-27 Merial, Inc. Canine influenza vaccines
EP2650017A2 (en) 2008-02-05 2013-10-16 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
EP2641612A1 (en) 2008-02-05 2013-09-25 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
WO2009100309A2 (en) 2008-02-08 2009-08-13 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
WO2009102488A2 (en) 2008-02-15 2009-08-20 Tufts University A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
US8324182B2 (en) 2008-02-15 2012-12-04 Tufts University Humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
EP2604280A2 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
EP2604279A1 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
US11319526B2 (en) 2008-05-02 2022-05-03 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2899203A2 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
US8425910B2 (en) 2008-07-09 2013-04-23 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
US9745375B2 (en) 2008-07-09 2017-08-29 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
EP2982695A1 (en) 2008-07-09 2016-02-10 Biogen MA Inc. Compositions comprising antibodies to lingo or fragments thereof
EP3597216A1 (en) 2008-08-11 2020-01-22 E. R. Squibb & Sons, L.L.C. Human antibodies that bind lymphocyte activation gene-3 (lag-3) and uses thereof
EP2905030A1 (en) 2008-08-11 2015-08-12 E. R. Squibb & Sons, L.L.C. Human antibodies that bind lymphocyte activation gene-3 (LAG-3) and uses thereof
EP4147714A1 (en) 2008-08-11 2023-03-15 E. R. Squibb & Sons, L.L.C. Human antibodies that bind lymphocyte activation gene-3 (lag-3) and uses thereof
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
EP3312198A1 (en) 2008-09-16 2018-04-25 Ganymed Pharmaceuticals GmbH Monoclonal anti-gt468 antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US8946388B2 (en) 2008-09-16 2015-02-03 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
EP3542815A1 (en) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
EP3168307A1 (en) 2008-11-28 2017-05-17 Merial Limited Recombinant avian influenza vaccine and uses thereof
EP2865689A1 (en) 2008-12-08 2015-04-29 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2949666A1 (en) 2008-12-19 2015-12-02 Biogen Idec International Neuroscience GmbH Human anti-alpha-synuclein antibodies
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
EP3521309A1 (en) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
WO2010078526A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2010084408A2 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
US11473085B2 (en) 2009-02-20 2022-10-18 Ganymed Pharmaceuticals Gmbh Methods and compositions for diagnosis and treatment of cancer
WO2010102175A1 (en) 2009-03-05 2010-09-10 Medarex, Inc. Fully human antibodies specific to cadm1
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
US8524869B2 (en) 2009-03-24 2013-09-03 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against LIGHT and uses thereof
WO2010112458A1 (en) 2009-03-31 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP2998315A2 (en) 2009-04-03 2016-03-23 Merial Limited Newcastle disease virus vectored avian vaccines
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
EP3009454A2 (en) 2009-04-20 2016-04-20 Oxford Bio Therapeutics Limited Antibodies specific to cadherin-17
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
EP3275900A1 (en) 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
WO2010125003A1 (en) 2009-04-27 2010-11-04 Novartis Ag Compositions and methods for increasing muscle growth
WO2010128398A1 (en) 2009-05-04 2010-11-11 Pangenetics 110 B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
EP3320920A1 (en) 2009-05-08 2018-05-16 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
EP3124613A1 (en) 2009-05-22 2017-02-01 Merial, Inc. Antibiotic-free plasmid
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
EP3659596A1 (en) 2009-07-20 2020-06-03 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with paclitaxel for the synergistic treatment of proliferative diseases
EP2769737A1 (en) 2009-07-20 2014-08-27 Bristol-Myers Squibb Company Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases
EP2947098A1 (en) 2009-07-20 2015-11-25 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with gemcitabine for the synergistic treatment of proliferative diseases
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US10030064B2 (en) 2009-10-06 2018-07-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US10059754B2 (en) 2009-10-06 2018-08-28 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011044180A1 (en) 2009-10-06 2011-04-14 Bristol-Myers Squibb Company Methods of production of glycoproteins in mammalian cell cultures using glucocorticoids
WO2011047083A1 (en) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Antibodies against epha10
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011056073A2 (en) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
EP3689911A1 (en) 2009-11-11 2020-08-05 Ganymed Pharmaceuticals GmbH Antibodies specific for claudin 6 (cldn6)
US10745477B2 (en) 2009-11-11 2020-08-18 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (CLDN6)
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
US11858988B2 (en) 2009-11-11 2024-01-02 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (CLDN6)
US9932401B2 (en) 2009-11-11 2018-04-03 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
EP4461354A2 (en) 2009-11-11 2024-11-13 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
EP3305813A1 (en) 2009-11-11 2018-04-11 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (cldn6)
WO2011057788A1 (en) 2009-11-11 2011-05-19 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
WO2011090708A2 (en) 2009-12-28 2011-07-28 Merial Limited Recombinant ndv antigen and uses thereof
EP3093025A1 (en) 2010-03-12 2016-11-16 Merial Inc. Bluetongue virus recombinant vaccines and uses thereof
WO2011112945A2 (en) 2010-03-12 2011-09-15 Merial Limited Foot and mouth disease virus recombinant vaccines and uses thereof
WO2011112955A1 (en) 2010-03-12 2011-09-15 Merial Limited Bluetongue virus recombinant vaccines and uses thereof
EP2944322A2 (en) 2010-03-12 2015-11-18 Merial Limited Bluetongue virus recombinant vaccines and uses thereof
WO2011116090A1 (en) 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
WO2011116885A1 (en) 2010-03-23 2011-09-29 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US9216218B2 (en) 2010-03-23 2015-12-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US10596256B2 (en) 2010-03-23 2020-03-24 TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH Monoclonal anti-GT 468 antibodies for treatment of cancer
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
EP3165540A1 (en) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
US10335485B2 (en) 2010-04-16 2019-07-02 Biogen Ma Inc. Anti-VLA-4 antibodies
US11083791B2 (en) 2010-04-16 2021-08-10 Biogen Ma Inc. Anti-VLA-4 antibodies
US11571477B2 (en) 2010-04-16 2023-02-07 Biogen Ma Inc. Anti-VLA-4 antibodies
US9718886B2 (en) 2010-07-06 2017-08-01 Ganymed Pharmaceuticals Ag Cancer therapy using CLDN6 target-directed antibodies in vivo
US10844133B2 (en) 2010-07-06 2020-11-24 Ganymed Pharmaceuticals Gmbh Cancer therapy using CLDN6 target-directed antibodies in vivo
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US9902778B2 (en) 2010-07-06 2018-02-27 Ganymed Pharmaceuticals Ag Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2012003956A1 (en) 2010-07-06 2012-01-12 Ganymed Pharmaceuticals Ag Cancer therapy using cldn6 target-directed antibodies in vivo
US10351617B2 (en) 2010-08-13 2019-07-16 Trustees Of Tufts College Compositions, kits and methods for treatment of complement-related disorders
EP3156070A2 (en) 2010-08-31 2017-04-19 Merial Inc. Newcastle disease virus vectored herpesvirus vaccines
EP4014989A1 (en) 2010-08-31 2022-06-22 Boehringer Ingelheim Animal Health USA Inc. Newcastle disease virus vectored herpesvirus vaccines
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
WO2012031099A2 (en) 2010-09-02 2012-03-08 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
US11981730B2 (en) 2010-09-02 2024-05-14 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
US8337850B2 (en) 2010-09-09 2012-12-25 Pfizer Inc. 4-1BB binding molecules
US8821867B2 (en) 2010-09-09 2014-09-02 Pfizer Inc 4-1BB binding molecules
EP3441404A1 (en) 2010-09-09 2019-02-13 Pfizer Inc 4-1bb binding molecules
WO2012032433A1 (en) 2010-09-09 2012-03-15 Pfizer Inc. 4-1bb binding molecules
US10640568B2 (en) 2010-09-09 2020-05-05 Pfizer Inc. 4-1BB binding molecules
US9468678B2 (en) 2010-09-09 2016-10-18 Pfizer Inc. Method of producing 4-1BB binding molecules and associated nucleic acids
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP3133088A1 (en) 2010-10-04 2017-02-22 Boehringer Ingelheim International GmbH Cd33 binding agents
WO2012045752A1 (en) 2010-10-04 2012-04-12 Boehringer Ingelheim International Gmbh Cd33 binding agents
WO2012045703A1 (en) 2010-10-05 2012-04-12 Novartis Ag Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
WO2012049570A1 (en) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Human anti-tau antibodies
WO2012058768A1 (en) 2010-11-05 2012-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP4023676A1 (en) 2010-11-15 2022-07-06 Novartis AG Silent fc variants of anti-cd40 antibodies
EP3222636A1 (en) 2010-11-15 2017-09-27 Novartis AG Silent fc variants of anti-cd40 antibodies
EP3502138A1 (en) 2010-11-15 2019-06-26 Novartis AG Silent fc variants of anti-cd40 antibodies
WO2012065950A1 (en) 2010-11-15 2012-05-24 Novartis Ag Silent fc variants of anti-cd40 antibodies
EP3628689A1 (en) 2010-12-17 2020-04-01 Neurimmune Holding AG Human anti-sod1 antibodies
WO2012080518A1 (en) 2010-12-17 2012-06-21 Neurimmune Holding Ag Human anti-sod1 antibodies
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US11008389B2 (en) 2011-03-16 2021-05-18 Sanofi Uses of a dual V region antibody-like protein
WO2012140627A1 (en) 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
EP3026064A1 (en) 2011-05-13 2016-06-01 Ganymed Pharmaceuticals AG Antibodies for treatment of cancer expressing claudin 6
US10233253B2 (en) 2011-05-13 2019-03-19 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US10919974B2 (en) 2011-05-13 2021-02-16 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
US11859008B2 (en) 2011-05-13 2024-01-02 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
WO2012156018A1 (en) 2011-05-13 2012-11-22 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
EP3421496A1 (en) 2011-05-13 2019-01-02 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
EP4464382A2 (en) 2011-05-13 2024-11-20 Astellas Pharma Inc. Antibodies for treatment of cancer expressing claudin 6
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2012166493A1 (en) 2011-06-01 2012-12-06 Merial Limited Needle-free administration of prrsv vaccines
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
EP3385280A1 (en) 2011-06-10 2018-10-10 MedImmune Limited Anti-pseudomonas psl binding molecules and uses thereof
EP3925978A1 (en) 2011-06-13 2021-12-22 AltruBio Inc. Anti-psgl-1 antibodies and uses thereof
WO2012177972A1 (en) 2011-06-23 2012-12-27 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
WO2013003625A2 (en) 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Antibodies
WO2013001369A2 (en) 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
WO2013003606A1 (en) 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
WO2013006437A1 (en) 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
US12281169B2 (en) 2011-07-11 2025-04-22 Ichnos Sciences SA Antibodies that bind to OX40 and their uses
WO2013008171A1 (en) 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
WO2013012446A1 (en) 2011-07-20 2013-01-24 Merial Limited Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
WO2013034660A1 (en) 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
US9316645B2 (en) 2011-10-07 2016-04-19 Brown University Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
US10196442B2 (en) 2011-11-01 2019-02-05 Bionomics Inc. Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to G protein-coupled receptor 49 (GPR49)
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
US9221906B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of inhibiting solid tumor growth by administering GPR49 antibodies
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2013078118A1 (en) 2011-11-21 2013-05-30 Bristol-Myers Squibb Company Methods for determining the susceptibility of a virus to an attachment inhibitor
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US9617336B2 (en) 2012-02-01 2017-04-11 Compugen Ltd C10RF32 antibodies, and uses thereof for treatment of cancer
WO2013119960A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Novel modulators and methods of use
EP3575794A1 (en) 2012-02-10 2019-12-04 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
EP3095797A1 (en) 2012-02-24 2016-11-23 Stemcentrx, Inc. Anti dll3 antibodies and methods of use thereof
WO2013142371A1 (en) 2012-03-20 2013-09-26 Merial Limited Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
US10525130B2 (en) 2012-03-26 2020-01-07 Sanofi Stable IGG4 based binding agent formulations
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP2662386A1 (en) 2012-05-07 2013-11-13 BioNTech AG Antibodies that bind to PLAC1 and block interaction between PLAC1 and FGF7
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
EP3666796A1 (en) 2012-05-09 2020-06-17 Astellas Pharma Inc. Antibodies against claudin 18.2 useful in cancer diagnosis
US11976130B2 (en) 2012-05-09 2024-05-07 Astellas Pharma Inc. Antibodies against claudin 18.2 useful in cancer diagnosis
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
WO2013167259A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies against claudin 18.2 useful in cancer diagnosis
US10053512B2 (en) 2012-05-09 2018-08-21 Ganymed Pharmaceuticals Ag Antibodies against claudin 18.2 useful in cancer diagnosis
EP4036119A1 (en) 2012-05-09 2022-08-03 Astellas Pharma Inc. Antibodies against claudin 18.2 useful in cancer diagnosis
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
EP3254695A1 (en) 2012-05-23 2017-12-13 GANYMED Pharmaceuticals AG Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4364756A2 (en) 2012-05-23 2024-05-08 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174509A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4119582A1 (en) 2012-05-23 2023-01-18 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3791896A1 (en) 2012-05-23 2021-03-17 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3725810A1 (en) 2012-05-23 2020-10-21 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174510A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4556071A2 (en) 2012-05-23 2025-05-21 Astellas Pharma, Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4556070A2 (en) 2012-05-23 2025-05-21 Astellas Pharma, Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013183032A2 (en) 2012-06-08 2013-12-12 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
WO2013188673A2 (en) 2012-06-13 2013-12-19 Merial Limited Reassortant btv and ahsv vaccines
US9334489B2 (en) 2012-06-14 2016-05-10 Sanofi CHO expression system
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
EP4553086A2 (en) 2012-07-02 2025-05-14 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2014008218A1 (en) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EP3795592A1 (en) 2012-07-02 2021-03-24 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EP3275899A1 (en) 2012-07-02 2018-01-31 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
EP3381943A1 (en) 2012-07-25 2018-10-03 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2014020331A1 (en) 2012-08-01 2014-02-06 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
WO2014058875A2 (en) 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
EP3750560A2 (en) 2012-10-09 2020-12-16 Biogen MA Inc. Combination therapies and uses for treatment of demyelinating disorders
WO2014062535A1 (en) 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP3766903A2 (en) 2012-11-13 2021-01-20 BioNTech SE Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
EP3575326A1 (en) 2012-12-17 2019-12-04 Trillium Therapeutics Inc. Treatment of cd47+ disease cells with sirp alpha-fc fusions
EP4116331A1 (en) 2012-12-17 2023-01-11 PF Argentum IP Holdings LLC Treatment of cd47+ disease cells with sirp alpha-fc fusions
EP3792278A2 (en) 2012-12-21 2021-03-17 Biogen MA Inc. Human anti-tau antibodies
WO2014102399A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
EP3517545A1 (en) 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
WO2014106602A1 (en) 2013-01-02 2014-07-10 Glenmark Pharmaceuticals S.A. Antibodies that bind to tl1a and their uses
WO2014122613A1 (en) 2013-02-08 2014-08-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EP4450086A2 (en) 2013-02-08 2024-10-23 Novartis AG Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EP3656786A1 (en) 2013-02-08 2020-05-27 Novartis AG Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
EP3736293A1 (en) 2013-02-12 2020-11-11 Boehringer Ingelheim International Gmbh Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4177273A1 (en) 2013-02-20 2023-05-10 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127906A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3556400A1 (en) 2013-02-22 2019-10-23 AbbVie Stemcentrx LLC Method of making antidll3-antibody pbd conjugates
WO2014130879A2 (en) 2013-02-22 2014-08-28 Stem Centrx, Inc. Novel antibody conjugates and uses thereof
WO2014146778A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3670537A1 (en) 2013-03-18 2020-06-24 Astellas Pharma Inc. Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014186364A2 (en) 2013-05-13 2014-11-20 Tufts University Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
US10053510B2 (en) 2013-05-24 2018-08-21 Promis Neurosciences Inc. FasR antibodies and methods of use
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
US10414823B2 (en) 2013-06-06 2019-09-17 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
US10421818B2 (en) 2013-06-06 2019-09-24 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
WO2014197849A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
EP3738611A1 (en) 2013-07-31 2020-11-18 BioNTech AG Diagnosis and therapy of cancer involving cancer stem cells
US10604568B2 (en) 2013-07-31 2020-03-31 BioN Tech AG Diagnosis and therapy of cancer involving cancer stem cells
US11795218B2 (en) 2013-07-31 2023-10-24 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EP3738612A1 (en) 2013-07-31 2020-11-18 Biontech AG Diagnosis and therapy of cancer involving cancer stem cells
EP3747465A1 (en) 2013-07-31 2020-12-09 BioNTech AG Diagnosis and therapy of cancer involving cancer stem cells
WO2015022658A2 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
EP3906945A2 (en) 2013-08-26 2021-11-10 BioNTech Research and Development, Inc. Nucleic acids encoding human antibodies to sialyl-lewis a
WO2015053871A2 (en) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
EP3338793A1 (en) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
EP2868328A1 (en) 2013-10-31 2015-05-06 Universitätsklinikum Regensburg IL-3 blockade in systemic lupus erythematosus and multiple sclerosis
EP2910645A1 (en) 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis upon antibody treatment
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
US10358500B2 (en) 2014-04-04 2019-07-23 Bionomics Inc. Humanized antibodies that bind LGR5
WO2015162590A1 (en) 2014-04-24 2015-10-29 Novartis Ag Methods of improving or accelerating physical recovery after surgery for hip fracture
EP3461495A1 (en) 2014-04-24 2019-04-03 Novartis AG Methods of improving or accelerating physical recovery after surgery for hip fracture
EP3888690A2 (en) 2014-05-16 2021-10-06 MedImmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
EP3498295A1 (en) 2014-05-28 2019-06-19 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
WO2015187811A2 (en) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
US10906988B2 (en) 2014-06-04 2021-02-02 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
EP3868405A1 (en) 2014-06-04 2021-08-25 BioNTech Research and Development, Inc. Human monoclonal antibodies to ganglioside gd2
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
US11760809B2 (en) 2014-06-04 2023-09-19 BioNTech SE Human monoclonal antibodies to ganglioside GD2
EP3610924A1 (en) 2014-06-06 2020-02-19 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EP3998079A1 (en) 2014-06-06 2022-05-18 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2016011448A3 (en) * 2014-07-18 2016-03-10 Celltheon Corporation Methods and compositions for expression of polypeptides in a cell
US10538799B2 (en) 2014-07-18 2020-01-21 Celltheon Corporation Methods and compositions for expression of polypeptides in a cell
EP4406549A2 (en) 2014-07-29 2024-07-31 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
WO2016050822A2 (en) 2014-09-30 2016-04-07 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
US10894818B2 (en) 2014-10-03 2021-01-19 Massachusetts Institute Of Technology Antibodies that bind Ebola glycoprotein and uses thereof
US10557125B2 (en) 2014-10-23 2020-02-11 Sanofi Selection marker for cell transfection and protein production
US11384342B2 (en) 2014-10-23 2022-07-12 Sanofi Selection marker for cell transfection and protein production
US12203103B2 (en) 2014-10-23 2025-01-21 Sanofi Selection marker for cell transfection and protein production
WO2016073410A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
EP3725808A1 (en) 2014-11-21 2020-10-21 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
US11873339B2 (en) 2014-12-11 2024-01-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
WO2016097865A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
EP3945096A1 (en) 2014-12-19 2022-02-02 Regenesance B.V. Antibodies that bind human c6 and uses thereof
WO2016106221A1 (en) 2014-12-22 2016-06-30 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
EP4249066A2 (en) 2014-12-23 2023-09-27 Bristol-Myers Squibb Company Antibodies to tigit
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
US11078512B2 (en) 2015-02-11 2021-08-03 Bristol-Myers Squibb Company Compositions for cell bioproduction and methods of using the same
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
WO2016134335A2 (en) 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
EP3978929A1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
EP4374916A2 (en) 2015-03-31 2024-05-29 MedImmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
EP3733701A1 (en) 2015-03-31 2020-11-04 MedImmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
WO2016164308A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
WO2016164305A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
EP3903804A1 (en) 2015-04-06 2021-11-03 Subdomain, LLC De novo binding domain containing polypeptides and uses thereof
EP4331578A2 (en) 2015-04-15 2024-03-06 Astellas Pharma Inc. Drug conjugates comprising antibodies against claudin 18.2
WO2016166122A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016166124A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016179517A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
EP3736290A1 (en) 2015-05-29 2020-11-11 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2016210094A1 (en) 2015-06-23 2016-12-29 Merial, Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
EP3889166A1 (en) 2015-06-23 2021-10-06 Boehringer Ingelheim Animal Health USA Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
EP3738975A1 (en) 2015-06-23 2020-11-18 Boehringer Ingelheim Animal Health USA Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
US10465011B2 (en) 2015-06-26 2019-11-05 Novartis Ag Factor XI antibodies and methods of use
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
WO2017009712A1 (en) 2015-07-13 2017-01-19 Compugen Ltd. Hide1 compositions and methods
EP3971211A1 (en) 2015-07-13 2022-03-23 Compugen Ltd. Hide1 compositions and methods
WO2017031353A1 (en) 2015-08-19 2017-02-23 Rutgers, The State University Of New Jersey Novel methods of generating antibodies
WO2017031120A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
WO2017048902A1 (en) 2015-09-15 2017-03-23 Board Of Regents, The University Of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
DE112016004398T5 (en) 2015-09-28 2018-06-14 Limited Liability Company "Oncomax" (Llc "Oncomax") THE ANTIBODIES THAT SPECIFICALLY BIND THE TYPE-1 RECEPTOR OF THE FIBROBLAST GROWTH FACTOR, THE USE OF ANTIBODIES FOR THE TREATMENT OF ONCOLOGICAL DISEASES, A PROCESS FOR THE PREPARATION OF THE ANTIBODIES
US10358499B2 (en) 2015-09-28 2019-07-23 Limited Liability Company “Oncomax” (Llc “Oncomax”) Antibodies which specifically bind fibroblast growth factor receptor 1, encoding nucleic acids thereof, and methods of producing thereof
EP4286002A2 (en) 2015-09-29 2023-12-06 Boehringer Ingelheim Animal Health USA Inc. Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
WO2017058521A1 (en) 2015-09-29 2017-04-06 Merial, Inc. Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
WO2017084078A1 (en) 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
WO2017132666A1 (en) 2016-01-29 2017-08-03 Merial, Inc. Recombinant adenovirus vectored fmdv vaccines and uses thereof
WO2017141208A1 (en) 2016-02-17 2017-08-24 Novartis Ag Tgfbeta 2 antibodies
EP4406550A2 (en) 2016-03-04 2024-07-31 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
WO2017152085A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017151176A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
WO2017156298A1 (en) 2016-03-10 2017-09-14 Medimmune, Llc Ilt7 binding molecules and methods of using the same
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
US11767364B2 (en) 2016-05-09 2023-09-26 Bristol-Myers Squibb Company TL1A antibodies and methods of treatment
WO2017196663A1 (en) 2016-05-09 2017-11-16 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
US10647780B2 (en) 2016-05-25 2020-05-12 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
WO2017205721A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2017207694A1 (en) 2016-06-02 2017-12-07 Kohlmann Angelica Antibodies that bind to human anti-müllerian hormone (amh) and their uses
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018013714A1 (en) 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3269740A1 (en) 2016-07-13 2018-01-17 Mabimmune Diagnostics AG Novel anti-fibroblast activation protein (fap) binding agents and uses thereof
US10077306B2 (en) 2016-07-14 2018-09-18 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2018013818A2 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
EP4512829A2 (en) 2016-07-14 2025-02-26 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US10533052B2 (en) 2016-07-14 2020-01-14 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US11591392B2 (en) 2016-07-14 2023-02-28 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US12312403B2 (en) 2016-07-14 2025-05-27 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US12558421B2 (en) 2016-08-17 2026-02-24 Compugen Ltd. Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
EP4043494A1 (en) 2016-09-23 2022-08-17 BioNTech SE Bispecific trivalent antibodies binding to claudin 6 or claudin 18.2 and cd3 for treatment of claudin expressing cancer diseases
WO2018054973A1 (en) 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
WO2018054484A1 (en) 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
US11993651B2 (en) 2016-10-11 2024-05-28 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
US10882908B2 (en) 2016-10-11 2021-01-05 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US12187795B2 (en) 2016-10-11 2025-01-07 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018071822A2 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
EP4289484A2 (en) 2016-12-07 2023-12-13 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US12012464B2 (en) 2016-12-23 2024-06-18 Novartis Ag Factor XI antibodies and methods of use
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
WO2018151821A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11827695B2 (en) 2017-02-17 2023-11-28 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP4678660A2 (en) 2017-03-24 2026-01-14 Novartis AG Antibody against activin receptor type ii receptor for use in treating heart failure
WO2018175460A1 (en) 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease
WO2018187613A2 (en) 2017-04-07 2018-10-11 Bristol-Myers Squibb Company Anti-icos agonist antibodies and uses thereof
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP4512477A2 (en) 2017-04-22 2025-02-26 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018195527A1 (en) 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018200430A1 (en) 2017-04-26 2018-11-01 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
EP4275698A2 (en) 2017-05-01 2023-11-15 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
US12006365B2 (en) 2017-05-05 2024-06-11 Vaccinex, Inc. Human anti-semaphorin 4D antibody
US11427634B2 (en) 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody
WO2018204895A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
WO2018209194A2 (en) 2017-05-12 2018-11-15 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
US12042534B2 (en) 2017-05-12 2024-07-23 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
WO2019003165A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. Anti-fam19a5 antibodies and uses thereof
US12162942B2 (en) 2017-06-28 2024-12-10 The Rockefeller University Anti-MERTK agonistic antibodies and uses thereof
WO2019003104A1 (en) 2017-06-28 2019-01-03 Novartis Ag Methods for preventing and treating urinary incontinence
US11613588B2 (en) 2017-06-28 2023-03-28 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US11859003B2 (en) 2017-08-21 2024-01-02 Adagene Inc. Method for treating cancer using anti-CD137 antibody
US11242395B2 (en) 2017-08-21 2022-02-08 Adagene Inc. Anti-CD137 molecules and use thereof
US12378319B2 (en) 2017-08-21 2025-08-05 Adagene Inc. Anti-CD137 molecules and use thereof
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. B7-h4 antibodies and methods of use thereof
US11306144B2 (en) 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
US11814431B2 (en) 2017-08-25 2023-11-14 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh Antibodies useful in cancer diagnosis
WO2019048489A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh Antibodies useful in cancer diagnosis
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Human antibodies to thomsen-nouvelle (tn) antigen
WO2019087115A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2019087094A1 (en) 2017-11-03 2019-05-09 Novartis Ag Anti-cd40 antibodies for use in treatment of sjögren's syndrome
EP4600353A2 (en) 2017-11-14 2025-08-13 Arcellx, Inc. D-domain containing polypeptides and uses thereof
WO2019099440A1 (en) 2017-11-14 2019-05-23 Arcellx, Inc. Multifunctional immune cell therapies
WO2019099433A2 (en) 2017-11-14 2019-05-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
US11306149B2 (en) 2017-12-27 2022-04-19 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
US11952427B2 (en) 2017-12-27 2024-04-09 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2019147152A1 (en) 2018-01-26 2019-08-01 Universidade Nova De Lisboa L2a5 antibody or functional fragment thereof against tumour antigens
US11692036B2 (en) 2018-02-02 2023-07-04 Adagene Inc. Anti-CTLA4 antibodies and methods of making and using the same
US11359016B2 (en) 2018-02-02 2022-06-14 Adagene Inc. Anti-CTLA4 antibodies and methods of making and using the same
US11952681B2 (en) 2018-02-02 2024-04-09 Adagene Inc. Masked activatable CD137 antibodies
WO2019157447A1 (en) 2018-02-12 2019-08-15 Trustees Of Tufts College Cd59 for inhibiting inflammasome activation
EP4442320A2 (en) 2018-02-12 2024-10-09 Trustees Of Tufts College Methods of inhibiting inflammasome activation
US12435145B2 (en) 2018-02-21 2025-10-07 Five Prime Therapeutics, Inc. B7-H4 antibody formulations
WO2019169212A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
US11939383B2 (en) 2018-03-02 2024-03-26 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods and use thereof
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US10640576B2 (en) 2018-04-10 2020-05-05 Y-Biologics Inc. Cell engaging binding molecules
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
US10836833B2 (en) 2018-04-10 2020-11-17 Y-Biologics Inc. Cell engaging binding molecules
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
WO2019198019A1 (en) 2018-04-13 2019-10-17 Novartis Ag Anti-cd40 antibodies for use in prevention of graft rejection
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US12162952B2 (en) 2018-04-27 2024-12-10 Neurimmune Ag Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibody
US12324841B2 (en) 2018-05-07 2025-06-10 Genmab A/S Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
US11970532B2 (en) 2018-05-10 2024-04-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
EP4074732A1 (en) 2018-05-11 2022-10-19 Wuxi Biologics (Shanghai) Co. Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
WO2019214624A1 (en) 2018-05-11 2019-11-14 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing same, and use thereof
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
WO2020003172A1 (en) 2018-06-26 2020-01-02 Mor Research Applications Transthyretin antibodies and uses thereof
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
US12509513B2 (en) 2018-06-29 2025-12-30 ApitBio, Inc. Anti-L1CAM antibodies and uses thereof
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
WO2020109978A1 (en) 2018-11-26 2020-06-04 Novartis Ag Lpl-gpihbp1 fusion polypeptides
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
US12492244B2 (en) 2019-01-02 2025-12-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2020144605A1 (en) 2019-01-11 2020-07-16 Novartis Ag Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
EP3683239A1 (en) 2019-01-17 2020-07-22 Beijing Mabworks Biotech Co. Ltd. Antibodies binding human claudin 18.2 and uses thereof
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
US11919962B2 (en) 2019-01-22 2024-03-05 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
US11008395B2 (en) 2019-01-22 2021-05-18 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
WO2020167912A1 (en) 2019-02-13 2020-08-20 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
WO2020176497A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
US11242407B2 (en) 2019-02-26 2022-02-08 Inspirna, Inc. High-affinity anti-MERTK antibodies and uses thereof
EP4378958A2 (en) 2019-02-26 2024-06-05 Inspirna, Inc. High-affinity anti-mertk antibodies and uses thereof
US12281174B2 (en) 2019-02-26 2025-04-22 Inspirna, Inc. High-affinity anti-MERTK antibodies and uses thereof
EP3935183A1 (en) 2019-03-04 2022-01-12 Beijing Mabworks Biotech Co. Ltd. Antibodies binding cd40 and uses thereof
WO2020188021A1 (en) 2019-03-19 2020-09-24 Sanofi Novel selection marker-comprising cell line and uses thereof for protein production
WO2020225736A1 (en) 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
US12540193B2 (en) 2019-05-31 2026-02-03 Trustees Of Tufts College Anti-ADAM8 antibodies and uses of the same
WO2020250159A1 (en) 2019-06-12 2020-12-17 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021025177A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021030488A1 (en) 2019-08-12 2021-02-18 Bienvenue David Leonard 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
WO2021048595A1 (en) 2019-09-11 2021-03-18 Novartis Ag A method for preventing human virus associated disorders in patients
WO2021058563A1 (en) 2019-09-23 2021-04-01 King's College London Dap10/dap12 fusion polypeptides
EP4566622A2 (en) 2019-09-23 2025-06-11 King's College London Dap10/dap12 fusion polypeptides
WO2021058091A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
WO2021058472A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
WO2021079002A2 (en) 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
US11820827B2 (en) 2019-12-30 2023-11-21 Seagen Inc. Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies
WO2021138264A1 (en) 2019-12-30 2021-07-08 Seagen Inc. Methods of treating cancer with nonfucosylated anti-cd70 antibodies
EP4085076A1 (en) 2020-01-03 2022-11-09 Biosion, Inc. Antibodies binding bcma and uses thereof
WO2021167964A1 (en) 2020-02-18 2021-08-26 Alector Llc Pilra antibodies and methods of use thereof
WO2021170020A1 (en) 2020-02-27 2021-09-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
EP4545566A2 (en) 2020-02-28 2025-04-30 The Brigham and Women's Hospital Inc. SELECTIVE MODULATION OF TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY SIGNALING VIA MULTISPECIFIC ANTIBODIES
WO2021176042A1 (en) 2020-03-06 2021-09-10 King's College London Therapeutic agents
US12216120B2 (en) 2020-03-26 2025-02-04 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2021228091A1 (en) 2020-05-12 2021-11-18 正大天晴药业集团股份有限公司 St2 antigen binding protein
EP4559477A2 (en) 2020-05-13 2025-05-28 Adagene AG Compositions and methods for treating cancer
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021233834A1 (en) 2020-05-17 2021-11-25 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of selecting and using the same
WO2021234163A1 (en) 2020-05-22 2021-11-25 King's College London Chimeric nkg2d protein
WO2021245184A1 (en) 2020-06-02 2021-12-09 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
WO2022018040A2 (en) 2020-07-20 2022-01-27 Astrazeneca Uk Limited Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
US12384841B2 (en) 2020-08-18 2025-08-12 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
US11725052B2 (en) 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
WO2022040345A1 (en) 2020-08-18 2022-02-24 Cephalon, Inc. Anti-par-2 antibodies and methods of use thereof
EP4454659A2 (en) 2020-08-18 2024-10-30 Cephalon LLC Anti-par-2 antibodies and methods of use thereof
WO2022051549A1 (en) 2020-09-04 2022-03-10 Rutgers, The State University Of New Jersey Sars-cov-2 vaccines and antibodies
EP4541812A2 (en) 2020-09-21 2025-04-23 Sanofi Generation of a high producing recombinant chinese hamster ovary cell line for therapeutic protein production
WO2022058603A1 (en) 2020-09-21 2022-03-24 Sanofi Generation of a high producing recombinant chinese hamster ovary cell line for therapeutic protein production
WO2022081779A1 (en) 2020-10-13 2022-04-21 Avitide LLC Affinity ligand libraries of three-helix bundle proteins and uses thereof
WO2022081775A1 (en) 2020-10-13 2022-04-21 Avitide LLC Aav8 affinity agents
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
WO2022101358A1 (en) 2020-11-11 2022-05-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2022119976A1 (en) 2020-12-01 2022-06-09 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
US11873333B2 (en) 2020-12-11 2024-01-16 The University Of North Carolina At Chapel Hill Compositions and methods comprising SFRP2 antagonists
US12258388B2 (en) 2020-12-11 2025-03-25 The University Of North Carolina At Chapel Hill Compositions and methods comprising SFRP2 antagonists
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
WO2022144406A1 (en) 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
WO2022143670A1 (en) 2020-12-30 2022-07-07 和铂医药(苏州)有限公司 Antibody capable of binding to trop2, and use thereof
EP4271712A1 (en) 2020-12-30 2023-11-08 Immunomic Therapeutics, Inc. Anti-hvem antibodies
WO2022178396A1 (en) 2021-02-19 2022-08-25 Avitide LLC Aav2 affinity agents
EP4421180A2 (en) 2021-03-23 2024-08-28 King's College London Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
WO2022200442A1 (en) 2021-03-23 2022-09-29 King's College London Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
WO2022203090A1 (en) 2021-03-25 2022-09-29 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2022200498A1 (en) 2021-03-26 2022-09-29 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
EP4596575A2 (en) 2021-03-26 2025-08-06 Arcellx, Inc. Multifunctional immune cell therapies
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022217019A1 (en) 2021-04-09 2022-10-13 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
WO2022263508A1 (en) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
WO2022262959A1 (en) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
WO2022262828A1 (en) 2021-06-18 2022-12-22 正大天晴药业集团股份有限公司 Anti-il-36r antibody and use thereof
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023064927A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable polypeptide complex
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
WO2023064929A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable polypeptide complex
WO2023091865A1 (en) 2021-11-08 2023-05-25 Celldex Therapeutics, Inc. Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023093816A1 (en) 2021-11-25 2023-06-01 诺纳生物（苏州）有限公司 Anti-siglec-15 antibody and use thereof
WO2023111095A2 (en) 2021-12-15 2023-06-22 King's College London Engineered immune cell
WO2023122327A2 (en) 2021-12-24 2023-06-29 Avitide LLC Chi domain affinity ligands and agents
WO2023152382A1 (en) 2022-02-14 2023-08-17 King's College London Artificial microrna construct
US12030927B2 (en) 2022-02-18 2024-07-09 Rq Biotechnology Limited Antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
WO2023193817A1 (en) 2022-04-08 2023-10-12 Adagene Pte. Ltd. Anti-cd28 antibodies and methods of use thereof
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023217987A1 (en) 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023242362A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/antigen-binding molecules and methods of use
WO2023242361A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn binding molecules and methods of use
WO2023242371A1 (en) 2022-06-15 2023-12-21 argenx BV Ph-dependent hsa-binding molecules and methods of use
WO2023242372A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/hsa binding molecules and methods of use
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024025911A1 (en) 2022-07-29 2024-02-01 Avitide LLC An affinity agent comprising a ligand that binds vce and comprises seq id no: 1
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024038187A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Assay for detection of il-33
WO2024054656A2 (en) 2022-09-09 2024-03-14 Avitide LLC Affinity agents
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
WO2024231440A1 (en) 2023-05-09 2024-11-14 Astrazeneca Ab Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof
WO2024235175A1 (en) 2023-05-12 2024-11-21 智泽童康(广州)生物科技有限公司 Anti-cldn6 antibody and use thereof
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
EP4530295A2 (en) 2023-09-07 2025-04-02 argenx BV Fcrn antagonists and methods of use
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025082594A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025083173A1 (en) 2023-10-17 2025-04-24 Linnane Pharma Ab Bacterial lon protease domains and their use in therapy
WO2025083076A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025104253A1 (en) 2023-11-17 2025-05-22 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025133694A1 (en) 2023-12-20 2025-06-26 argenx BV Fcrn/hsa-binding molecules and methods of use
WO2025133186A1 (en) 2023-12-22 2025-06-26 OncoC4, Inc. Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies
WO2025157132A1 (en) 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025191498A1 (en) 2024-03-12 2025-09-18 Adaptam Therapeutics, S.L. Anti-siglec-15 antibodies and uses thereof
WO2025196207A1 (en) 2024-03-20 2025-09-25 King's College London Compositions and methods for use in depleting senescent cells and treating aging
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025202495A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2025261951A1 (en) 2024-06-18 2025-12-26 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies
WO2026041780A2 (en) 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment
WO2026057545A1 (en) 2024-09-10 2026-03-19 Neurimmune Ag Anti-sting antibodies and methods of use thereof
WO2026057739A1 (en) 2024-09-12 2026-03-19 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment

Also Published As

Publication number Publication date
US5658759A (en) 1997-08-19
JP2505268B2 (en) 1996-06-05
EP0323997B1 (en) 1993-04-21
DE3880468T2 (en) 1993-09-09
EP0323997A1 (en) 1989-07-19
GB8717430D0 (en) 1987-08-26
ATE88501T1 (en) 1993-05-15
US5591639A (en) 1997-01-07
DE3880468D1 (en) 1993-05-27
JPH02500330A (en) 1990-02-08

Similar Documents

Publication Publication Date Title
US5658759A (en) Recombinant DNA expression vectors
CA1268436A (en) Enhanced production of proteinaceous materials in eucaryotic cells
EP0309237B1 (en) A transient expression system for producing recombinant protein
EP0873405B1 (en) Expression augmenting sequence elements (ease) for eukaryotic expression systems
US6015708A (en) Gene manipulation and expression using genomic elements
Schmidt et al. Replicating foamy virus-based vectors directing high level expression of foreign genes
AU662416B2 (en) Recombinant DNA method and host cells
EP0073657A1 (en) Preparation of hepatitis B surface antigen in yeast
JPH0732712B2 (en) Recombinant DNA sequences, vectors containing them and methods of using them
WO1989010404A1 (en) Recombinant dna methods, vectors and host cells
AU660671B2 (en) Methods for selection of recombinant host cells expressing high levels of a desired protein
EP0351585B1 (en) Vector containing a chicken beta-actin gene promoter for the expression of a desired gene
CA2058280A1 (en) Expression systems
CA1339654C (en) Gene therapy using gene fusion for genetic or acquired disorders
US5747308A (en) Recombinant DNA method
JP2648301B2 (en) Vector containing auxiliary DNA for transformation of eukaryotic cells
CA1310601C (en) Expression vectors
JPH0231681A (en) Amplification of gene
JPS63126483A (en) Production of desired protein in myeloma cell
Sunao et al. Tandem gene amplification in vitro for rapid and efficient expression in animal cells
EP0054223A2 (en) Plasmid vectors for eukaryotic cells and method for selecting transfected eukaryotic cells
US5646010A (en) Methods and compositions for expression of competent eukaryotic gene products
AU602664B2 (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
AU610830B2 (en) A process for the preparation of human antithrombin III (ATIII), vectors and hosts cells suitable for this purpose, biologically active ATIII obtained in this way, and medicaments containing the latter
US5919650A (en) Method for inactivation of protein function

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988906008

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988906008

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1988906008

Country of ref document: EP